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Mycobacterium tuberculosis is the causative organism for one of the pandemic diseases 
in the world, tuberculosis (TB). The length of treatment often results in multi-drug 
resistance (MDR) and patient non-compliance. One of the most important enzymes as a 
drug target for tuberculosis is dihydrofolate reductase (DHFR), which plays an 
important role in the folate cycle and inhibition of the enzyme stops cell growth. DHFR 
inhibitors are usually 2,4-diaminopyrimidines, which have high binding affinity to the 
enzyme but have the potential to inhibit the human enzyme. This project focuses on the 
development of new inhibitors with improved potency and selectivity for the M. 
tuberculosis enzyme. Inhibitors containing a 5-phenyl group were targeted in order to 
increase lipophilicity and binding to the enzyme, whilst reducing binding to the human 
enzyme. Condensation of diethyl phenylmalonate with guanidine followed by 
chlorination and amination of the carbonyl group gave 2-amino-6-chloro-4-p-
methoxybenzylamino-5-phenylpyrimidine, which was deprotected to give 6-chloro-2,4-
diamino-5-phenylpyrimidine. Reaction of 2-amino-6-chloro-4-p-methoxybenzylamino-
5-phenyl-pyrimdine with different aromatic and aliphatic amines was also investigated. 
Amination with an amino alcohol in presence of potassium carbonate in the absence of 
solvents was used to synthesise a number of analogues. Deprotection of the p-
methoxybenzylamine was achieved by DDQ oxidation to give the desired 2,4-diamino-
5-phenyl-6-aminoalcohol-pyrimidine products. The synthesis of the triol motif began 
with protection of ribonolactone and reduction of the carbonyl group to give the diol. 
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1.1 The Genus Mycobacterium 
 
The genus mycobacterium comes from the family Mycobacteriacea. The bacteria are 
thin, non-motile, and non-spore-forming, with a slightly curved shape and the genus 
contains more than 50 species.1 They are gram positive bacteria2 and can be found in 
water, soil, and food. Mycobacteria require long incubation times, specific media, and 
specific temperature to grow. They are also aerobic, and grow in environments containing 
3-11 % CO2.1 
 
1.1.1 Classification of Mycobacterial species 
Mycobacterial species are divided into two groups in terms of their growth: rapid, and 
slow growing. Some new species of both groups have been discovered in the last ten 
years.1 Examples of fast growing bacteria are M. chelonae and M. fortuitum, both of 
which  cause skin infections. An example of the slow growing bacteria is the 
Mycobacterium avium complex (MAC), a heterogeneous group of mycobacterial 
organisms that can affect the bronchi and lymph nodes, such as M. kansassi which causes 
pulmonary disease. M. tuberculosis complex is also slow-growing, and includes the 
specific species M. tuberculosis, M. bovis, M. africanum, M. microti, and M. caprae. M. 
bovis can be transmitted through unpasteurized milk.1 Any of the M. tuberculosis 
complex microorganisms can cause tuberculosis in humans.3 The slow growing 
microorganisms can be further subdivided into three classes. Photochromogenic, refers to 
organism's cells that produce pigments when exposed to light. In contrast, 
scotochromogenic organisms produce pigments constitutively even in the absence of 
light. Non-chromogenic organisms do not produce pigments at all. Organisms in the  M. 
tuberculosis complex are non-chromogenic.1  
Another method of classifying  mycobacterial species is their pathogenicity, which is 
the ability of the organism to cause infectious disease. The first class is pathogenic 
mycobacteria, mainly M. tuberculosis. Mycobacteria other than M. tuberculosis are 
often referred to as MOTT, which stands for mycobacteria other than tubercle bacilli. 
MOTT are also called atypical mycobacteria, meaning they are not contagious. The 
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second class is the non-pathogenic mycobacteria. Many mycobacteria that are non-
pathogenic are normal flora found in humans.1   
 
1.1.2 The organism M. tuberculosis 
 
One mycobacterial species, M. tuberculosis, is considered to be the causative pathogen 
of tuberculosis, which infects one–third of the world's population.4 Robert Koch 
discovered that M. tuberculosis was the bacteria responsible for the disease tuberculosis 
in 1882. This disease is considered an epidemic, with around 9.8 million new victims a 
year.5 For this reason, considerable efforts are focused on enhancing the treatment of 
tuberculosis. Because poor environmental conditions are considered to be the main 
cause for the spread and transmission of tuberculosis, improving these environments is 
also of high priority.5 
 
M. tuberculosis grows in highly oxygenated environments,6 which is why the disease 
often presents with pulmonary symptoms. The bacterium appears as a rod shape when 
examined by microscopy and is related to actinomycetes, which are a heterogeneous 
group of gram-positive bacteria with filamentous growth shapes.7 M. tuberculosis is 
pathogenic with a slow generation time, between 15-20 hours.6  
 
1.1.3 Morphology of M. tuberculosis 
 
The cell wall structure of mycobacteria is unique among all eukaryotes and prokaryotes. 
It was first described by Minnikin in 1982.8 The cell envelope consists of a cytoplasmic 
membrane comprising of a phospholipid bilayer, which is surrounded by a 
peptidoglycan cell wall.9 The cytoplasmic membrane acts as a barrier.2 The 
peptidoglycan layer is absent in plants, animals, and humans, unlike the bacteria, and it 
is  thicker in gram positive bacteria than in gram negative.10  
The cell wall of M. tuberculosis (Figure 1) also contains specialised very-long-chain 
fatty acids (60-90 carbon atoms) known as mycolic acids.11 Mycolic acids contain 
number of unusual features and cyclopropane rings. It has been reported that the 
mycolic acid structure consists of α, β, keto methoxymycolates at the proximal and 
distal ends.4 The exact structure of the mycolic acid layer has still not been completely 
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determined but it is known to play an essential role because any changes or mutations in 
the mycolic acid layer are fatal to the mycobacteria, as this changes the cell wall’s 
permeability. The mycolic acid layer makes up about 30-40% of the cell wall.1   
 
Linking the mycolic acid and peptidoglycan layers is the arabinogalactan layer,2,11 also 
known as as the electron dense outer layer, electron translucent region,9 or murein 
layer.10 The layer comprises a linear polymer of galactose with branched 
arabinogalactan molecules.2 Another layer of the cell wall structure of M. tuberculosis is 
the lipoarabinomannan (LAM) layer. The LAM layer which is a bulky polymer of 
arabinose and mannose intercalates the arabinogalactan layer (Figure 1).12 
                         
                                 
Figure 1: The cell wall structure of M. tuberculosis. 
1- Outer lipids, 2- Mycolic acid, 3- Polysaccharides (arabinogalactan), 4- Peptidoglycan, 5- Plasma 
membrane, 6- Lipoarabinomannan (LAM), 7- Phosphatidylinositol mannoside, 8- Cell wall 
skeleton. 
 
1.1.4 The effect of the cell wall structure of M. tuberculosis on its pathogenicity 
 
Because of the lipid nature of the cell membrane, a substance has to dissolve in it in 
order to penetrate the membrane. Hydrophilic compounds generally require protein 
transporters to help them penetrate the lipid layers of the M. tuberculosis cell 
membrane. These transporters, such as the porin channels, are in the outer membrane of 
the mycobacteria. It has been suggested that these channels are connected to the inner 
layer of the cell membrane to facilitate the efflux of drugs and thus mediate resistance to 
antibiotics. Thus, they could be a treatment target for tuberculosis.2  
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Virulent strains of M. tuberculosis also possess cord factor, which is a surface 
glycolipid.13 It is very toxic to mammalian cells, as it enhances acute and chronic 
tuberculosis and interferes with the action of isoniazid which is one of the first line 
drugs used to treat tuberculosis.14 Some mycobacteria form structures such as capsules 
and biofilm, which are also associated with virulence. However, there is no exact 
information about their mechanism.2 
 
The high lipid content in the cell wall, formed by the mycolic acid-arabinogalactan-
peptidoglycan layers, gives mycobacteria many characteristics. For example the layer 
confers resistance to some anti-tuberculosis drugs.2 The drug resistance is due to the 
high hydrophobicity, and hence acts as a permeability barrier. This hydrophobicity also 
makes the cell wall impermeable to acids (referred to as acid fastness)9 and gives the 
mycobacteria the ability to survive inside macrophages.6 The cell wall is also 
responsible for the immune response often observed following bacterial attack on the 
human body9(Figure 1). 
 
The presence of the cell wall allows identification of mycobacteria by acid-fast staining. 
The mycobacterial cells are treated with a red carbolfuchsin dye and then exposed to 
heat. Thereafter, the cells are treated with acid or alcohol to remove the red colour of the 
carbolfuchsin dye. These colourless cells are treated with methylene blue but the cells 
retain the red colour of the carbolfuchsin because the acid or alcohol does not wash off 
the initial red colour.1  
 
1.2  Classification of the disease tuberculosis 
 
Tuberculosis can be classified into three phases, according to the stage in the 
pathogenesis of the disease. First is the active or primary phase, which occurs upon 
infection. Second is the latent phase,15 in which the disease becomes dormant. Third is 
the post-primary disease phase, which occurs when people who recover from the 
primary disease are re-exposed to mycobacteria.16 
 
  Another method of classifying the disease is based on the location of the infection.   
When the organism affects the lungs, it is called pulmonary tuberculosis, which is the  
most common type. If the organism causes lesions and shows up on the chest X-ray as 
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“millet seeds,” this is called miliary tuberculosis.  Extrapulmonary tuberculosis includes 
infection of any organ other than the lungs, such as the lymph nodes (also known as 
lymphanditis). Mycobacteria can also affect the central nervous system (CNS) and 
cause meningitis. Other organs that are less commonly affected by M. tuberculosis are 
the gastrointestinal tract (GIT), bones, and joints. Infection of the GIT, which may cause 
ascites (accumulation of fluids), was common in the past and occurred through 
ingestion of milk contaminated with M. bovis.16 
 
1.2.1 Aetiology and transmission 
 
There are many risk factors that increase the chance of contracting tuberculosis.15,16 
These factors include: close contact with infected people, poor nutrition, drug addiction; 
alcoholism and diabetes mellitus. In the last twenty-five years co-infection of HIV 
patients has also become an increasing problem. Other factors that make a tuberculosis 
epidemic more likely are poor living or working conditions and wars.15 
 
1.2.2 Pathogenesis of tuberculosis 
 
Tuberculosis can be transmitted by air by patients with an active pulmonary or laryngeal 
tuberculosis, cough, or sneeze, or even through talk. If bacilli are inhaled by another 
person, the inhaled bacilli can pass through the bronchi, reach the terminal alveoli in the 
lungs and cause active primary disease.16 Inhaled droplet nuclei are 1-5 nm in diameter, 
and they are especially easily transmitted in small, crowded places that allow close 
contact. Extrapulmonary tuberculosis (an infection that occurs outside the lungs) 
accounts for a larger proportion of cases in countries in which the incidence of 
tuberculosis is relatively low, such as Western Europe and North America. However, 
more than 85% of  tuberculosis cases worldwide are pulmonary.15 
In the case of pulmonary tuberculosis, when the inhaled droplets reach the lungs, they 
are engulfed by macrophages. Inside the macrophages, the M. tuberculosis bacilli 
multiply and immune response components, such as cytokine and interferon, they are 
secreted in response. Usually the immune response occurs approximately two to eight 
weeks after the initial infection. There are two mechanisms for the macrophage immune 
response; first, the phagosome that contains the M. tuberculosis is infused with a 
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lysosome. This infusion causes bacterial lysis, forming toxic compounds. In the second 
mechanism, the ubiquitin peptide penetrates the mycobacterial membrane thus allowing 
access of toxic compounds into the permabilised cells. When the macrophages secrete 
immune components, the infection starts. However, these components cannot destroy 
the mycobacteria. The mycobacterial bacilli can avoid the fusion between the 
phagosome and the lysosome (first mechanism) and can escape from the macrophages 
with the help of some antigenic proteins that are secreted in the initial phase. However, 
other macrophages will engulf the escaped bacilli again to continue the immune 
response.15 
A granuloma can also be formed as a result of the immune response. There are two 
types of granuloma; caseous granulomas consist of epithelial macrophages, neutrophils, 
and fibroblasts. In contrast, fibrotic granulomas consist of fibroblasts only. 
Mycobacterial cells can be present in three locations in these tuberculosis lesions. Most 
of the cells are extracellular, located in the wall of the cavity lesion, some of the cells 
are inside the caseous lesions; and others are inside the acid milieu of the macrophages.6 
The tubercule bacilli can also infect other organs, such as the central nervous system 
(CNS), kidneys, bones, and liver. Normally, development of a granuloma prevents 
mycobacteria from spreading to other sites in the body, and should lead to 
mycobacterial death. However, virulence factors in M. tuberculosis cells, such as the 
intracellular growth of mycobacteria in the macrophages, leads to ineffectiveness of the 
immune response. Mycobacteria can also resist radical reactive oxygen species 
produced during phagocytosis. The slow generation time of the mycobacteria also 
results in a delay in the immune system’s ability to recognise the organism. Moreover, 
the presence of cord factor15 results in death of macrophages and causes a caseating 
granuloma through interaction with lipids.14 These factors reduce mycobacterial cell 
death and increase the persistence of the infection.  
 
Because M. tuberculosis bacilli have the ability to form spores they are tolerant to low 
O2 levels, low levels of nutrients, the pH in the alveoli and the toxic radicals secreted by 
macrophages by becoming dormant for years. This dormant state is called latent 
tuberculosis and generally has few symptoms. However, the disease can be re-activated 




1.2.3 Diagnosis of tuberculosis 
Early diagnosis increases the probability of successful treatment. The World Health 
Organisation (WHO) reported 63% of tuberculosis cases in 2009 because of delayed 
diagnosis. Delayed diagnosis is a common cause of tuberculosis becoming an epidemic, 
and this happens when the patient delays asking for medical help for any reason, 
especially if they have poor access to healthcare or diagnostic systems. Lack of reliable 
diagnostic tests or availability in many countries raises both the incidence and mortality 
rate of tuberculosis.17  
 
The first diagnostic step is to perform microscopy on the patient's sputum, but more 
than one sample at different times is required because the long growth time of the 
mycobacteria means that a false negative result can be obtained. Tuberculosis can also 
be diagnosed using a chest X-ray since around 80% of cases are pulmonary. The disease 
appears as shadowing in the upper lobe or as fluids around the lungs.11  Another method 
for diagnosis is the tuberculin test, which is is used for detecting the initial immune 
response and is most effective when performed six to eight weeks after the infection. 
The test requires intradermal injection of a purified protein  derivative (PPD) from M. 
tuberculosis, which results in visible swelling of the skin due to an enhanced immune 
reaction.16 Latent tuberculosis has few symptoms and generally requires the use of 
molecular biology techniques to determine the presence of bacterial genomic 
sequences.15  
Some countries have a system of diagnosis called point of care (POC), which detects 
diseases such as HIV and hepatitis. These tests work by detecting the antibodies that 
have been produced by the human body as an immune response to infection. These tests 
have the advantage that they can be used in hospital or community settings without the 
need for laboratory facilities. In the case of M. tuberculosis infection there are some 
biological markers which are produced as part of the immune response.  To detect these 
biological markers, there are some tests are called interferon-γ release assays, which 
detect patients with latent tuberculosis who were vaccinated by BCG. However, it is 
impossible to differentiate between the active and the latent stages of the disease. Also, 
there are some tests that detect antigens produced in response to M. tuberculosis 
infection, which can be used for blood or sputum samples. However, most of these 
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diagnostic tests have not been approved by WHO. There are ongoing studies to look for 
diagnostic tests that detect the metabolites from both the mycobacteria and the host.17  
1.2.4  Epidemiology: 
WHO has estimated tuberculosis incidence, prevalence, and mortality cases worldwide. 
It has been reported that 9.4 million new cases of infection and 1.78 million deaths are 
caused by tuberculosis every year. Of these cases, 14% are co-infected with HIV and 
86% are patients infected by multi-drug resistant (MDR) strains.22 The highest 
tuberculosis infection rates are found in Asia followed by Africa, and this is due to the 
spread of HIV in Africa. The highest proportion of multi-drug resistant cases is found in 
India and China.18 
 
1.2.5  Signs and symptoms of tuberculosis 
 
Primary tuberculosis patients are asymptomatic,15 whilst pulmonary tuberculosis 
patients show many signs and symptoms. These include the coughing up of blood, 
weight loss, fever, fatigue, shortness of breath, and chest pain. Childhood tuberculosis 
can be asymptomatic and, in many cases, causes meningitis. Miliary tuberculosis, which 
occurs after the primary phase of disease, causes weight loss, anorexia, and fatigue.16 
 
1.2.6 Prevention of tuberculosis 
 
There are two types of tuberculosis preventions. A pharmacological intervention 
involves vaccinating healthy people against tuberculosis. The other intervention is a 
non-pharmacological intervention, which involves isolating the infected person in a 
separate room, thus preventing spread of the disease.6 
 
The BCG (Bacille Calmette–Guérin) vaccine is currently used at birth. While the 
vaccine has shown to be effective for over ten- fifteen years, it does not prevent the 
adult tuberculosis disease. There is a need to develop a vaccine that can be more 
effective than BCG. A vaccine based on the heat shock protein HSP60 is now 
considered to prevent the reactivation of active tuberculosis.6 This vaccine has some 
effectiveness against both pre- and post-exposure to mycobacteria.19 
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Vaccination is the best preventive method, especially for latent tuberculosis. There are 
more than ten vaccines in clinical trials, two of which are recombinant M. bovis BCG. 
Some of these vaccines are also used as booster vaccines to control the immune 
response after exposure to BCG. Studies on vaccines to prevent the reactivation of 
tuberculosis are ongoing, continuing the search for a good replacement for BCG.15   
The studies to find a BCG replacement are focused mainly on the immune cells. Many 
studies have shown that prevention mainly depends on the immune cells  especially the 
T-cells and the interleukin because of their ability to produce toxins that attack bacteria. 
These studies are focused on enhancing protection against the first exposure to bacteria, 
which prevents the reactivation of the latent tuberculosis and also lowers the chance of 
latent tuberculosis development.20 
 
1.2.7 Treatment of tuberculosis 
 
Before the 20th century, the only available treatment of tuberculosis was bed rest, good 
nutrition and a healthy environment.6 At the beginning of the 20th century, the cell wall 
structure of M. tuberculosis became the main target of study, especially after penicillin 
and sulphonamides had been shown to be ineffective at treating tuberculosis.21 During 
the 1940s, the first drugs for tuberculosis treatment were introduced, streptomycin and 
p-aminosalicylic acid. Isoniazid was then released and became the most effective anti-
tuberculosis drug. Ethambutol was introduced in the 1960s to replace p-aminosalicylic 
acid because of its side effects. Therapy usually required eighteen to twenty four months 
of treatment. However, upon the introduction of rifampicin as a treatment in the 1970s, 
the standard course of treatment was reduced to six to nine months.6 
 
1.2.8 First line drugs  
The first line treatment of tuberculosis uses a combination therapy in which isoniazid, 
rifampicin, streptomycin, and pyrazinamide are administered at the same time. Each of 
these drugs in this regimen acts on a different bacterial target and has a specific 
mechanism of action. This initial treatment usually lasts for two months, during which 
time the patient has daily administration of the four drugs. Following completion of this 
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course of treatment, the patient receives isoniazid and rifampicin three times a week for 
the next four months. 21 
1.2.8.1 Isoniazid           
 
Isoniazid is a prodrug that is activated by a peroxidase enzyme to produce isonicotinic 
acid (Scheme 1). Isoniazid inhibits mycolic acid synthesis by inhibition of two 
enzymes: inhA enzyme, and a complex of an acyl carrier protein (AcpM) and β-
ketoacyl synthase (KasA) enzymes. InhA, AcpM and KasA enzymes are required for 
the activation of isoniazid prodrug and they are also involved in the synthesis of 
mycolic acid.22 Isoniazid is highly active against rapidly growing bacteria.6 Isoniazid 
has a bacteriostatic effect against inactive mycobacteria. It also has an effect on DNA 
and carbohydrates by interfering with multiple enzymes that are responsible for DNA 
metabolism.21 It is the most powerful drug to treat tuberculosis, but it has a few 
uncommon side effects such as insomnia, anxiety, and an influenza-like syndrome.16 
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Rifampicin is a broad spectrum bacteriostatic antibiotic. It disrupts the nucleic acid 
biosynthesis by inhibiting the activity of DNA-dependent RNA polymerase.22 
Rifampicin is the second most powerful anti-tuberculosis drug. It has a bactericidal 
effect against the intracellular M. tuberculosis bacilli. It has some effect at both the 
initial infection stage, as well as the later stages of tuberculosis. Rifampicin has some 
side effects, such as thrombocytopenia, skin reactions, and an influenza-like syndrome. 
Rifampicin is metabolised by hepatic cytochrome P450 enzymes and drug-drug 





Pyrazinamide is used for short-term therapy of tuberculosis. It has a bacteriostatic effect 
against inactive mycobacteria, mediated by disruption of the mycobacterial cell 
membrane.6 Pyrazinamide is a prodrug that is converted to the active form pyrazonic 
acid (PZO) by pyrazinamidase (Scheme 2). Pyrazonic acid is not readily cleared by the 
antibiotic efflux system and accumulates in the bacterial cytoplasm, leading to a 
reduced pH and inhibition of fatty acid synthase, which is required for fatty acid 
biosynthesis.22 Pyrazinamide has some unwanted side-effects such as hepatotoxicity, 
anorexia, and photosensitisation.16 
 
 









1.2.8.4  Ethambutol 
 
                                   
 
Ethambutol is an inhibitor of the arabinosyltransferase enzyme,21 which affects the 
polysaccharide layers and inhibits the conversion of D-glucose to D-arabinose residues. 
As a result, synthesis of the arabinogalactan layer of the mycobacterial cell wall is 
disrupted.6 Ethambutol therefore has a bacteriostatic effect.23 The main side effect of 
ethambutol is optic neuritis, which causes visual changes and often goes unnoticed by 
children (unless children and parents are counselled to watch out for such changes). 
Other side effects of ethambutol include jaundice and skin rash.16  
 
1.2.8.5. Streptomycin:  
 
Streptomycin is transferred to the bacterial cells by active transport. It disrupts the 
transcription of the genetic code, and as a result, it inhibits the protein synthesis of the 
mycobacterial cell wall.6 Streptomycin has some unwanted side effects, such as allergic 
reactions, renal impairment, and dermatitis.16  
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1.2.9  Second line drugs 
 
There are a number of second line drugs that can be used for treatment of tuberculosis, 
but these antibiotics have many side effects, are expensive, and are less selective against 
M. tuberculosis. Second line antibiotics include capreomycin, cycloserine, amikacin, 
ciprofloxacin, and fluoroquinolones.2 Because of the unwanted side-effects of second 
line drugs, they are  primarily used in the treatment of resistant bacteria.6 
 
1.2.10 Multi-drug resistance (MDR) 
 
Microbial antibiotic resistance occurs when a previously effective drug treatment 
becomes less effective. It differs from the phenomenon of insensitivity, in which the 
antibiotic is always ineffective. Infections caused by resistant micro-organisms respond 
less well to treatment and they cause increased mobidity and mortality. The first report 
of drug resistant tuberculosis was in the 1940s.4 A further complication is that some 
strains of mycobacteria are naturally resistant to at least one of the first line drugs used 
for treatment of tuberculosis; thus, new treatments should begin with a combination of 
drugs to maximise effectiveness and minimize the emergence of new resistant strains. 
Mycobacterial resistance can occur simultaneously against isoniazid and rifampicin, the 
most powerful anti-tuberculosis drugs. The WHO calls this multi-drug resistant 
tuberculosis.6 
 
There are many risk factors that increase the possibility of multi-drug resistance. These 
include: long-term administration of anti-tuberculosis drugs, close contact with other 
patients infected with multi-drug resistant strains, patients who are immuno-
compromised, such as those co-infected with HIV, drug and alcohol addiction, 










1.2.10.1 Classification of drug resistance 
 
Drug resistance is classified by the WHO into four groups:  
 Mono-resistance, in which tuberculosis strains are resistant to a single drug 
(usually isoniazid or streptomycin).  
 Double resistance, in which strains are resistant to both isoniazid and 
streptomycin.  
 Triple resistance, in which strains are resistant to isoniazid, streptomycin, and 
rifampicin.  
 Quadruple resistance, which occurs when strains are resistant to isoniazid, 
streptomycin, rifampicin, and ethambutol.6 
 
1.2.10.2 Types of multi drug resistance 
 
There are two main sub-types of multi-drug resistance. Primary resistance occurs when 
patients are infected by tuberculosis strains which are already resistant. Acquired 
resistance is where the patient is infected by non-resistant strains but resistance 
subsequently develops. Most of the cases of multi-drug resistance are acquired,24 and 
this is partly a consequence of the long treatment times which are required due to the 
slow growth of the mycobacteria. 
1.2.10.3 Extensive drug resistance (XDR) 
Extensive drug resistance (XDR) is a situation in which mycobacterial cells become 
resistant to the second line drugs, especially to fluoroquinolones,25 in addition to their 
resistsance to the first line drugs.5 In 2008 the WHO reported that 5.4% of multi-drug 
resistant strains had extensive resistance, with eight cases reported in the U.K. In 2010 
there were fifty three thousand reported cases of multi-drug resistance, of which sixty 
were reported in the U.K.26 MOTTs can also become resistant to anti-tuberculosis 





1.2.10.4  Mechanism of resistance 
The specific mechanism of resistance differs depending on which specific antibiotic is 
used. Generally any non-lethal mutation or change in any gene of mycobacterial cells 
will result in resistance if this affects the antibiotic function of the drug. For example, 
isoniazid is activated by catalase (specific type of peroxidase enzyme) to create 
isonicotinic acid (Scheme 1), any mutation that reduces the activity of this enzyme will 
lead to inactivation of the isoniazid since the pro-drug is less efficiently converted into 
the active antibiotic. Mycobacterial resistance to isoniazid can also result from 
mutations in a protein called Inh-A, which is responsible for mycolic acid synthesis.6 
The mechanism of rifampicin resistance is related to mutations of RNA polymerase, 
which is responsible for nucleic acid synthesis. Likewise, streptomycin resistance arises 
due to mutation of ribosomal RNA genes6 or the transporters which are responsible for 
the active transport of streptomycin through the bacterial cells.16 
Isoniazid and rifampicin are effective against the extracellular bacilli, often located 
inside caseous lesions and macrophages, while pyrazinamide is effective against the 
intracellular cells where the environment is acidic. In the latent stage, isoniazid, 
rifampicin, and pyrazinamide fight bacteria slowly. Discontinuing the therapy 
prematurely is likely to cause resistance6 due to incomplete eradication of the 
mycobacteria. Multi-drug resistance can also occur due due to a combination of drugs.23 
 
1.2.10.5  Treatments of tuberculosis multi-drug resistance 
Treatment of tuberculosis with first line drugs regimen is effective in up to 95% of 
tuberculosis patients. In cases of multi-drug resistance development, treatment with 
second line drugs with DOT (Direct Observed Therapy) is effective in 50-70% cases. 
Treatment of extensive drug resistance is difficult because the standard first and second 
line drugs are less effective. The patient is usually treated with a combination of eight to 
ten drugs for twenty four months with DOT, but highly toxic side effects, such as 
nephrotoxicity and hepatotoxicity are often observed.5 Other factors that need to be 
considered are:  
 The risk of the patient developing MDR.  
  The expense of the therapy.  
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 The likelihood of the disease been transmitted to others.27  
Direct observed therapy (DOT) is required for patients who are at high risk of 
developing MDR, such as those co-infected with HIV. Patients who are not able to 
complete the treatment or  have to be treated intermittently also require the use of direct 
observed therapy.6 
 
Patients who are suspected of having MDR infections should not have further drugs 
added to their existing regimen. Instead the existing drugs should be replaced by the 
injectable second line drugs and treatment should be continued for at least twenty four 
months. In addition patients should undergo direct observed therapy to ensure better 
compliance and the infection tested for susceptibility.6 
 
There are approximately twenty second line drugs for the treatment of tuberculosis. 
These include; injectable drugs, such as fluoroquinolones, which are effective in 
treatment of MDR, ethionamide, which inhibits mycolic acid synthesis, cycloserine, 
which inhibits peptidoglycan and arabinogalactan synthesis and amikacin, which, like 
rifampicin, inhibits bacterial RNA synthesis. The problem with these drugs is that they 
are less effective in the treatment of latent tuberculosis. Patients co-infected with HIV 
have the additional complication that the drugs used to treat this infection can interact 
with those used to treat tuberculosis. For example, protease inhibitors used to treat HIV 
often interact with rifampicin.28 
1.2.11 Classifications of the anti-mycobacterial compounds regarding their 
mechanism of action 
The anti-mycobacterials can be subdivided according to their mechanism of action. For 
example, isoniazid, pyrazinamides, pyrazoles, and nitroimidazopyrans all inhibit fatty 
acid biosynthesis. Cycloserine (Figure 5), ethylenediamines, and arabinose analogues all 
affect arabinogalactan or peptidoglycan biosynthesis and thus compromise the bacterial 
cell wall. The aminoglycosides, cyclic peptides, and macrolides inhibit protein 
biosynthesis, whilst rifampicin, fluoroquinolones, purine, and pyrimidine analogues 
inhibit nucleic acid biosynthesis and the deazapteridines and benzimidazoles which 
interfere with tubulin polymerisation and therefore inhibit cell division. Salicylamide 
and its analogues interfere with the biosynthesis of siderophores, which are required for 
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uptake of iron into the mycobacterial cells. Azoles inhibit the action of cytochrome P450 
enzymes. Branched chain amino acid biosynthesis is inhibited by sulfometuron methyl, 
whilst signal transduction is inhibited by the salicylanilides, benzothiophenes, and 
nitropyrroles. There are also some miscellaneous inhibitors such as those which inhibit 
isocitrate lyase (an essential enzyme required for the bacterial glyoxylate cycle), the 
peptide deformylase inhibitors, and the pyridazinoindoles which inhibit monoamine 
oxidase. Finally there are the diaminopyrimidines, triazines, and deazapteridines, which 
interfere with folate metabolism by inhibiting dihydrofolate reductase (DHFR), the drug 
target examined in this project.21 
                                        
Finding an efficient treatment for multi-drug resistance is difficult because of 
mycobacteria’s long generation time, latent stage, and low metabolic activity. Because 
the location of the bacteria is inside the human body (e.g. in the pulmonary cavity or 
inside the lesions), this makes the delivery of the antibiotic to the bacteria difficult.21 
1.2.12 Other treatment regimens and new antimycobacterial agents for 
tuberculosis 
DOT is useful with patients who cannot complete the course of treatment or those who 
have intermittent treatment, such as that in the Denver regimen. The Denver regimen 
can be applied in two ways. In the first way, the first line drugs are administered daily 
for two weeks. The frequency of administration is then decreased to twice a week for 
another six weeks, followed by administration of isoniazid and rifampicin only twice a 
week for another sixteen weeks. The second method involves administration of the first 
line drugs three times a week for eight weeks, then the same dosage of isoniazid and 
rifampicin for eighteen weeks.27 For both ways, DOT should be accompanied with drug 
toxicity monitoring.6 
There are other regimens that have been investigated on latent tuberculosis patients that 
are currently under study. For example, one regimen studied in the UK involves the 
administration of isoniazid and rifampicin daily or twice a week for three months. 
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Another regimen that is under investigation is administration of isoniazid and 
rifapentine (a rifampicin analogue) once a week accompanied by DOT. The Centre for 
Disease Control (CDC) has suggested another treatment strategy. This treatment 
consists of six to twelve months of fluoroquinolones or ethambutol administered with 
pyrazinamide. Unfortunately, this regimen appears to be less effective.29  
A more promising investigation involved rifapentine (Figure 6), a cyclopentyl 
rifampicin derivative used in a trial study on tuberculosis patients who were HIV 
negative. The administration of rifapentine combined with isoniazid once a week 
showed some effectiveness in these patients, but was not effective in HIV positive 
patients.29  
















There are anti tuberculosis approved drugs, such as imipenen, which are effective 
against both multi and extensive drug resistance, however, there still is not enough 
information about its effectiveness in humans (Figure 7).29  
                                         
Another drug called meropenem,29 which is a carbapenem, shows some activity against 
M. tuberculosis strains when it is combined with a β-lactamase inhibitor (Figure 8). 
Additionally, thioridazine has shown some activity in murine models against 
tuberculosis and multi-drug resistance strains through two interesting functions. It 
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inhibits bacterial efflux and ion transport in macrophages, allowing destruction of 
bacterial cells.29 
                                          
It has been reported that nine months of isoniazid treatment was curative for up to 90% 
of latent tuberculosis patients, but close observation of liver function and side effects is 
required. It has been reported that the administration of rifampicin alone for nine 
months showed lower hepatotoxixity.30  
To find appropriate regimens to treat latent tuberculosis, animal models have been used 
to investigate the effectiveness of various drugs. For instance, the administration of 
rifapentine and moxifloxacin once weekly for three months was shown to be as 
effective as nine months of daily isoniazid. Another example of an animal tested drug is 
diarylquinolone, which proved to be better than isoniazid during the early stage of 
tuberculosis and better than rifampicin in the latent stage. Also 1,2-ethylendiamine was 
shown to be effective against tuberculosis in animal models. Scientists expect that these 
drugs will be used for the treatment of latent tuberculosis in the future.15  
The search for an appropriate treatment of latent tuberculosis is still ongoing. 
Examination of tuberculosis shows that a functional glyoxylate shunt is important for 
maintaining the mycobacteria in a dormant state. The glyoxylate shunt is a modification 
of the tricarboxylic acid cycle in which the oxidative steps are bypassed, allowing the 
mycobacteria to utilise alternative carbon sources. The two key enzymes in the 
glyoxylate shunt are isocitrate lyase and malate synthase. Inhibitors of these two key 
enzymes have been shown to be effective for the treatment of latent tuberculosis.4 
Multi-drug resistance is another problem that studies have focused upon. 
Fluoroquinolones are bacteriocidal, and are recommended for treatment of multi-drug 
resistance because of their bioavailability. Moreover, fluoroquinolones have no cross-
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resistance with other resistant drugs.29 Molecular techniques can be used to characterise 
resistant strains to determine the specific mutations present in a particular strain.24 
1.2.13 Tuberculosis studies: 
1.2.13.1 Studies based on screening techniques 
Some of the new studies that target tuberculosis are focused on the genome sequencing 
of M. tuberculosis, and these kind of studies have still not shown any large effect.5 One 
of these studies was based on screening enzymes and identifying their inhibitors. This 
method was useful for targeting mycobacterial growth; however, this method did not 
help in determining the biological target. The same study investigated a phenotypic 
screening of the bacterial cell, which gives a picture of the interaction between drug 
targets and any constituents of the bacterial cell. This kind of screening has led to a 
discovery of new anti tuberculosis drug candidates, such as diarylquinolines (TMC 
207), which affect ATP synthesis, and benzothiazines (BTZ043), which affect arabinan 
synthesis (Figure 9).5  










1.2.13.2 Reengineering of existing scaffolds 
Kaul et al.5 reported another approach for looking for new tuberculosis drugs, which are 
generated from existing antibiotics. These studies require reengineering of existing 
scaffolds, which means a modification is made to existing anti-mycobacterials to 
enhance their activity and other properties to achieve a better outcome. For example, 
oxazolidinones (linezolid) are anti-mycobacterial drugs that have been modified to give 
a better activity against M. tuberculosis and lower  toxicity (Figure 10).5 
 
                
Another example are the nitroimidazole anti-folates, which are effective against 
anaerobic bacteria and parasites; however, they are still in clinical studies to test their 
affect on latent tuberculosis after their modification (Figure 11).5 
                       
1.2.13.3 Nanotechnology-based techniques 
Tuberculosis studies have progressed to the application of nanotechnology for 
improving the drug delivery system. Nanoparticles give more effective and compliant 
therapy. A number of nanotechnologies have been reported, such as nanosuspensions 
(dispersions of pure nanosized particles) which enhance drug solubility. 
Nanosuspensions have been tested in vivo and have given interesting results in the 
development of new anti-tuberculosis drug formulations.25 
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Another nanotechnology that has been investigated is the use of nanoemulsions, the oil 
in water-based dispersion of drug particles. They are easy to prepare on a large scale 
and deliver.25  
Niosome is a technique that allows flexibility in structure characterization of the drug. 
Polymeric nanoparticles also have been investigated and have shown improved stability 
of both hydrophilic and hydrophobic drugs.25  
Modifying the surface of anti-tuberculosis drugs to make them more hydrophilic is a 
process called encapsulation. This technique will protect the anti-tuberculosis drugs 
from the immune response of infected patients. When applied to isoniazid and 
rifampicin, this technique led to higher intracellular bioavailability. Liposome or 
microsphere encapsulated anti-tuberculosis drugs are more effective than free drugs. 
Liposomes, nano vesicles that surround the encapsulation core of the drugs, will 
increase the length of release of the drugs.25 
1.2.13.4 Tuberculosis studies on HIV patients 
Many studies have focused on HIV patients who have tuberculosis. These patients are 
suffering from drug interactions between the antimycobacterial drugs and the anti-
retrovirals, which lead to toxicity and immune reconstitution inflammatory syndrome. 
Therefore, studies have focused on the amount of time of using these anti-retroviral 
drugs. If the administration of anti-retrovirals is delayed until completion of the 
tuberculosis treatment course, this would cause death due to HIV progression. To 
overcome this problem, WHO recommended that treatment with anti-retrovirals should 
start within two to eight weeks after a patient begins a regimen of anti-tuberculosis 
drugs.31 
1.2.13.5 Inhaled therapy for tuberculosis 
Inhaled therapy for tuberculosis has been investigated. Inhaled therapy targets the lungs, 
the macrophages, and the dendritic cells that are produced by the immune system. This 
form of therapy reduces the side effects of anti tuberculosis drugs. These studies are still 
ongoing, though aerosol BCG vaccine has been tested on animals and has shown good 
activity.32 Inhaled nanoparticles for the treatment of pulmonary tuberculosis are also 
beneficial as a local drug delivery system with low systemic side effects.25 
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1.2.13.6 Studies on second line drugs for tuberculosis 
One type of second line drugs are quinoxalines, which are interesting antibacterial 
drugs. Moreno et al.33 and his group synthesized many quinoxaline-1,4-di-N-oxide 
derivatives that they had tested on specific strains of M. tuberculosis. Primary 
screenings showed some activity. Moreno et al. and his team have reported some 
considerations for the development of quinoxaline-1,4-di-N-oxide derivatives as anti-
mycobacterials. For instance, the quinoxaline ring with carboxamide at position 2, a 
methyl motif at position 3, and an electron withdrawing group at position 6 or 7 or both,  
they are all attached to an aromatic ring via a linker, such as a methylene group (Figure 
12).33 
                     
Shunduru et al.34 reported a synthesis of 2,4,6-trisubstituted-1,3,5-triazines derivatives, 
which was started from the previous reports about the pyrimidino-triazines compounds 
that have anti-leishmanial activity with moderate antibacterial activity (Figure 13). 
Studies found that 1,2,3 triazine moiety is important for anti-tuberculosis activity, 







                  
 
Rajni et al.35 reported a study that focused on the cell wall structure of mycobacteria, 
virulence factors, and the pathogenesis of the initial and the latent stages of the disease. 
They have reported that guanosine triphosphatase was a drug target for tuberculosis. 
The functional enzyme is required for the persistence of the bacteria and allows the 
mycobacteria to escape from the lysosome. They suggested that drugs targeting the GTP 
enzyme could provide novel treatments for latent tuberculosis.35 
1.2.14  Dihydrofolate reductase (DHFR) 
Prokaryotic and eukaryotic cells need folate to synthesise many cellular components.36 
Metabolic processes requiring folate include synthesis of nucleic acids and the 
regeneration of methionine. Oxidation and reduction of a one-carbon unit is required 
during these processes. Prokaryotes can synthesise folate while eukaryotes obtain folate 
from food or as supplement. The structure of folic acid consists of 2-amino-4-oxopter-
idine, p-aminobenzoic acid and glutamic acid.36(Figure 14).  




1.2.14.1 Folate cycle 
Folate metabolism involves several reactions that modify the carbon atom that attaches 
to nitrogen atom N5, N10, or both of the folate structure (Figure 14).37 The most 
important enzyme in folate metabolism is dihydrofolate reductase (DHFR), which 
reduces dihydrofolate to tetrahydrofolate using NADPH. The NADPH transfers a 
hydride anion to C6 of the pteridine ring,40 with concurrent protonation at N5 position41 
(Scheme 3). The latter is required for biosynthesis of thymidylate and purines used for 
DNA and RNA synthesis, methionine, and several amino-acids.38 Tetrahydrofolate is a 
carrier of a one-carbon unit, and it is formed by a reduction of 7, 8-dihydrofolate by 
DHFR. THF is converted to 5,10 methylene-THF by the interconversion of serine to 
glycine, which is catalyzed by serine hydroxymethyltransferase (SHMT).37 5,10-
methylene-THF is then converted to dihydrofolate during thymidine synthesis. 
Deoxythymidylate (dTMP) is formed from deoxyuridylate (dUMP) by thymidylate 
synthetase (TS) using 5,10-methylenetetrahydrofolate as the source of the methyl group. 
The 7,8-dihydrofolate produced during this reaction is reduced to tetrahydrofolate by 
DHFR, thus allowing regeneration of the cofactor. So, TS and DHFR perform important 



































































































Six enzymes are important for folate metabolism; the scheme below shows the 
involvement of these enzymes (Scheme 4 ).42 
GTP                                       Dihydroneopterin-PPP       
                                               
                                             Dihydroneopterin 
 
                               Hydroxymethyl-7,8-dihydropteridine 
 
                       Hydroxymethyl-7,8-dihydropteridine-PP + pABA 
 
                                               Dihydropteroate 
 
                                                  Dihydrofolate 
 
                                                 Tetrahydrofolate 
Thymidine DNA                  Purines DNA, RNA                        Methionine 
 
Scheme 4 : Enzymes involved in folate cycle. 
1-GTP cyclohydrolase; 2- Dihydroneopterin aldolase; 3- 6-hydroxymethyl-7,8-dihydropterin 















1.2.14.2  M. tuberculosis DHFR three-dimensional structure 
DHFR structure of M. tuberculosis consists of a general fold of central β-sheets with 
four α-helices. The central β-sheet consists of seven parallel strands and a single C-
terminal strand, which is an anti-parallel strand. The coenzyme NADPH is bound in an 
extended conformation by the C-terminal strand of the β-sheet, while the nicotinamide 
ring is inserted between strands β-a and β-f.38  
1.2.14.3  DHFR inhibitors 
There are many DHFR inhibitors that have been studied43 for selectivity and potency 
against many bacterial and protozoal diseases. Because of the role of DHFR in DNA 
and RNA biosynthesis, these drugs are also used for treating cancer. The most well-
known inhibitor that binds tightly to DHFR is methotrexate (MTX) (Figure 15), which 
is a 2,4-diaminopyrimidine derivative. The structure below shows that methotrexate  is 
an analogue of the dihydrofolate structure. The pteridine moiety contains an amino 
group instead of the carbonyl and the nitrogen atom of the p-aminobenzoic acid moiety 




The conversion of the 4-keto group in dihydrofolate to 4-NH2 group makes it a strong 
inhibitor because the amino group will form hydrogen bonds with the amino acids in the 
binding site of M. tuberculosis DHFR (Figure 15). Crystallographic studies have shown 
in very high resolution that methotrexate is in the protonated state in the binding site. 
Replacement of the NH2 group at position 4 with SH, OH or CH3 results in weaker 
inhibitors because hydrogen bonding with the amino acids in the binding active site of 
M. tuberculosis DHFR is lost.44 
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Methotrexate is also used as an anticancer drug. It is very potent against human DHFR, 
but because of its polar glutamic acid side-chain it needs active transport into cells.43 
Other examples of anti-folate drugs are trimethoprim and pyrimethamine (Figure 16). 
These are very effective drugs for the treatment of bacterial and protozoal infections.45 
There are also a number of very potent inhibitors of bacterial and protozoal enzymes, 
such as trimetrexate and piritrex,38 but these drugs have serious side-effects. 
Comparison of the human and M. tuberculosis DHFR structures can be used to optimise 
selectivity of an inhibitor for the mycobacterial enzyme and thereby decrease the 
possibility of serious side-effects.  
                          
                          
                                        
1.2.14.4 DHFR inhibitor studies 
Before 1930, the idea of the selectivity of chemotherapeutic treatment was not common 
because of lack of information about the detailed biochemical pathways in both 
eukaryotic and prokaryotic cells. The field was totally changed by the discovery of 
sulfonamide and its mechanism of action as an antibacterial. Sulfonamides compete 
with p-aminobenzoic acid in the synthesis of folic acid and this leads to the inhibition of 
cell growth due to the reduced availability of folate.41 
In 1948, Hitching and his team discovered 2,4-diaminopyrimidines.46 This discovery 
was followed by many studies centred around the development of drugs, including the 
nature of the enzymes or receptors that are involved are drug targets. The goal of these 
studies was to enhance the potency and selectivity of the 2,4-diaminopyrimidines. These 
studies led to the discovery of different classes of anti-folates with different selectivity 
and a broad spectrum. The studies also investigated the factors that increase the binding 
affinity to the enzymes from different species. 41 
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DHFR inhibitors are used to treat many human diseases, including fungal infections, 
psoriasis, rheumatoid arthritis, and cancer. DHFR has become the focus of chemical and 
molecular biological studies because of its utility as a drug target. However, some cells 
do not respond to DHFR inhibitors because they do not synthesize thymidylate and 
DNA, which are the main pathways requiring folate. 41 
1.2.14.5 Bacterial DHFR  
Folates are produced by de novo synthesis in bacteria and plants. Kompis et al.45 
reviewed the DHFR inhibitor literature between 1995 and 2004. Inhibitors of enzymes 
that are involved in the de novo folate cycle are known as anti-folates, for example, 
thymidylate synthase inhibitors, dihydropteroate synthase inhibitors, and serine 
hydroxymethyltransferase inhibitors.47  
The active site of the mammalian DHFR is larger than the bacterial DHFR. In human 
DHFR the pteridine ring is attached in the opposite orientation in comparison to other 
DHFRs. The amino group on the human DHFR forms only one H-bond with amino acid 
residues in the active site, while bacterial DHFRs form two H-bonds. There are 
approximately 167 structures of bacterial DHFRs with various ligands bound in the 
PDB "protein data bank".47 
Other enzymes involved in de novo folate cycle have also been investigated as anti-
tuberculosis drugs. For example, dihydropteroate synthase (DHPS) is a protein located 
in the bacterial cytoplasm; it is the target for sulfonamide and sulfone drugs. Many 
studies have investigated Escherichia coli, Staphylococcus aureus, and M. tuberculosis 
DHPS enzymes as drug targets.47  
Another enzyme that has been investigated is thymidylate synthase, which is 
responsible for utilising N5, N10-methylene THF. Inhibition of thymidylate synthase 
causes thymineless death, and this is a therapy for cancer. Many studies have examined 
the structure and mechanism of thymidylate synthase. There are 114 structures of 
thymidylate synthase in PDB "Protein data bank". However, there are no selective 
inhibitors for thymidylate synthase. One of the most interesting findings is that some 
parasites have a bifunctional DHFR-TS enzyme, including Plasmodium species, 
Toxoplasma gondii, and Leishmania. This finding could be useful in the design of new 
specific inhibitors for parasites in the future.47  
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Another enzyme that has been studied is serine hydroxymethyl transferase (SHMT), 
which is responsible for the conversion of serine to glycine using a tetrahydrofolate 
cosubstrate. Inhibitors of human SHMT have been used to treat cancer, but they have 
been shown not to be selective for the enzyme. Some DHFR inhibitors, such as triazine 
anti-folates, have been found to also inhibit SHMT. Some bacteria lack the presence of 
DHFR enzyme, such as Helicobacter pylori and Treponema palladium, which also lack 
the TS gene.47 
There have been many studies that have focused on the structure and mechanism of 
DHFR. Czekster et al.48 studied the kinetic and chemical mechanism of M. tuberculosis. 
The DHFR mechanism involves the protonation step at N5 with the water molecule and 
transfer of a hydride anion at C6. This study investigated the order of the two steps. 
There are two possible models that could occur. One model is the protonation at N5 first 
followed by hydride transfer. The other model is that O4 is protonated first, which leads 
to a hydride transfer to C6, followed by N5 ring protonation. The kinetic isotope effects 
and the effect of changing pH on rates of both steps suggest a mechanism in which 








1.2.14.6 Development of new DHFR inhibitors 
In the development of DHFR inhibitors, there are three types; The first type comprises 
the current anti-folate drugs. The second type are the newer DHFR inhibitors that are in 
the market, for instance trimetrexate, which is active against Plasmodium carinii and  
brodimoprim, which is a TMP analogue, but has a longer half-life. The third class of 
anti-folates is still under investigation; iclaprim, it has a higher activity against gram-
positive bacteria, piritrexim, is active against M. avium and it is used to treat 
methotrexate-resistant cells and epiroprim. It is used against M. ulcerans in combination 
with dapson. Epiroprim has a synergistic effect against M. leprae. All of these three 





Diseases currently treated using anti-folates include malaria, pneumonia caused by 
Plasmodium carinii, fungal diseases caused by Candida albicans, and protozoal 
diseases caused by Toxoplasma gondii. Because methotrexate is hydrophilic, it has 
limited access to cells. Lipophilic anti-folates, such as metoprine, piritrexim, and 
trimetrexate, are also useful for treating resistant cells.44 Bag et al.49 investigated  novel 
DHFR inhibitors of opportunistic microorganisms, including Plasmodium carinii, 
Toxoplasma gondii, and Mycobacterium avium, by synthesizing novel compounds that 
mimic the pharmacophore of anti-folates (such as the 2, 4-diaminopyrimidines), 
followed by biological evaluation. Computational studies were applied to investigate the 
binding modes of these drugs and their interactions with the enzyme.49 
1.2.14.7 Classification of antifolates based on their structures 
There are two structural classes of anti-folates: first, classical anti-folates, which are 
analogues of folic acid and contain an acidic moiety; Second, non-classical anti-folates, 
which are lipophilic folic acid analogues that lack the glutamic acid moiety. An example 
of a non-classical anti-folate is epiroprim, which was tested against M. tuberculosis and 
had no activity. Triazine DHFR WR99210 (Figure 18), however, showed good activity 
against M. tuberculosis without selectivity.47 Triazines, discovered as anti-folates in 
1952,44 are more potent inhibitors of mammalian enzymes than of bacterial enzymes.50 
Another example of a non-classical anti-folate is 2,4-diaminopyrimidine-5-
deazapteridines, which showed good activity against M. avium.47  
                              
Structure activity relationships of anti-folates reveal that the pharmacophore of 2,4-
diaminopyrimidine or triazines structures with lipophilic group at position 5 are 
important for flexibility.50 Pyrimidines like 5-benzyl-2,4-diaminopyrimidine are the 
largest and most potent of the 2,4-diaminopyrimidine derivatives. Quinazolines are 
another nonclassical anti-folate, they are more lipophilic than methotrexate. 
Quinazolines and methotrexate  have an  antileukemic effect.44 
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1.2.14.8  The dihydrofolate-binding site 
Many studies have shown that lipophilic 2,4-diaminopyrimidines are potent DHFR 
inhibitors. They are being used as lead compounds for development of novel anti-folate 
inhibitors.51 These 2,4-diaminopyrimidines, however, unfortunately lack selectivity 
against many pathogens.43 
To describe simply the binding site of the DHFR inhibitor to the M. tuberculosis 
enzyme, the most common feature is the formation of many hydrogen bonds with 
different protein residues. Compared to the human enzyme, there are many differences 
between them, which has led to many studies looking to improve the binding affinities 
of compounds in the mycobacterial DHFR binding site. There is, for example, a 
glycerol molecule binding close to N8 of methotrexate and the aminopyrimidine ring of 
trimethoprim through hydrogen bonds to Asp27, Gln28 and Leu24 of M. tuberculosis 
DHFR, and the glycerol carbon atoms are in contact with Leu20. Studying the glycerol 
molecule helps provide a template for developing a functional group that can form three 
hydrogen bonds with the hydroxyl groups of the glycerol molecule.38 
1.2.14.9 The differences between mycobacteria and human DHFR 
The main differences between the mycobacterial and human DHFR are as follows: 
 Human DHFR contains 187 amino-acids while mycobacterial DHFR contains 159. 
 The human enzyme is larger than the mycobacterial enzyme. 
 A glycerol molecule is bound close to the  DHF-binding site of M. tuberculosis, as 
shown by the crystal structure. Although it is not clear whether this glycerol is 
present in the enzyme in the cell or is an artefact of crystallisation, the ease with 
which it binds suggests that it is an accessible binding motif. This glycerol forms 
hydrogen bonds with Asp27, Gln28 and Leu24.38 Glycerol is absent from the structure 
of the human enzyme; the human enzyme has hydrophobic residues (Leu22, Pro26 and 
Phe31) occupying this space instead. The presence of this glycerol-binding motif 
allows the design of drugs which bind selectively to the mycobacterial enzyme, while 
not binding to the human enzyme.45 
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The structural comparison of the mycobacterial with the human DHFR is beneficial to 
develop a novel selective inhibitors of Mycobacterium tuberculosis DHFR. 
Because of tuberculosis treatment side effects and poor compliance from tuberculosis 
patients, studies have focused on the discovery of novel drugs that act as DHFR 
inhibitors. These studies explore their selectivity and potency in the DHFR binding site.  
1.2.14.10 DHFR 3-dimentional structure studies               
The protein data bank now has over ten lead compounds for potential treatment of M. 
tuberculosis. Studying the structures of these compounds is important. One method that 
can be used to study and examine the binding interactions of these compounds, is 
structural interaction fingerprint (SIF). Kumar et al.52 used SIF for mycobacterial DHFR 
virtual screening. The three known classes of mycobacterial DHFR inhibitors used in 
the screening showed the same binding signature at the hydrophobic pocket and the 
heteroatom ring, bearing the N atom bound to active site residues via H-bonding. These 
inhibitors were 2,4-diaminopyrimidines, deazaptridine derivatives, and triazines. Also, 
the phenyl side-chains of these inhibitors bind to the protein by hydrophobic contacts 
with amino acids. Therefore, the newly discovered compounds should have the same 
pharmacophore and binding interactions. This method of screening is the quickest way 
to identify compounds that interact with the enzyme.52 
Gargaro et al.53 studied the structure of Lactobacillus casei DHFR using NMR 
techniques in complex with methotrexate. Previous studies have combined NMR with 
X-ray crystallography to determine the binding site interactions, and this study was the 
first to investigate the binding site interactions using NMR techniques only. The 
structure of Lactobacillus casei DHFR with methotrexate obtained by NMR spectra was 
compared with the corresponding X-ray structure. The study concluded that NADPH 
binds more tightly to the DHFR-methotrexate complex than to DHFR alone. This kind 
of investigation will open the gate for further studies to understand binding specificity 
via different methods other than X-ray crystallography.53 Methylbenzoprim (Figure 19) 
is a potent anti-folate which binds more tightly to human enzymes than to bacterial 
enzymes. Studies have investigated the conformations of methylbenzoprim at the active 
site of human enzyme using molecular modelling and X-ray crystallography to increase 























2. Aim and objectives 
This project focuses on the development of a novel selective inhibitor of M. tuberculosis 
DHFR, based on that reported in a previous study.45 The designed molecules will 
incorporate those structural features known to be important for tight binding to DHFR 
and for selectivity towards the M. tuberculosis enzyme. Thus the target compounds will 
all contain a 2,4-diaminopyrimidine moiety, a common feature of potent DHFR 
inhibitors (Figure 19). A glycerol moiety will also be included in the inhibitor, as this 
will promote binding to the M. tuberculosis enzyme and disfavour binding to human 
DHFR, thus allowing selective inhibition of the mycobacterial enzyme. Binding of this 
glycerol moiety is mediated by a number of hydrogen bonds. The X-ray crystal structure 
of M. tuberculosis DHFR complexed with methotrexate and glycerol will be used to 
estimate the distance of the spacer unit for the inhibitor glycerol moiety. Examination of 
DHFR inhibitors such as trimethoprim and pyrimethamine, which are selective for 
bacterial enzymes, shows the presence of aromatic substitutents which are important for 
binding. The chance of interactions between this aromatic ring and hydrophobic 
residues within the active site is very high.45 
2.1 Aim of the project 
The aim of this project is to develop a lead compound that will bind tightly and 
selectively to M. tuberculosis DHFR. The project will focus on exploring the DHFR 
binding site using a linker at position 6 containing either a O, N or S atom. The 
synthesis of 2,4-diaminopyrimidines derivatives leading to 5-phenyl-2,4-
diaminopyrimidine derivatives with different side chains at position 6 of the pyrimidine 









1. Investigate synthesis of the 2,4-diamino-5-phenyl pyrimidine and trihydroxy alkyl 
side-chain (‘glycerol’) motifs followed by linking the two motifs together; 
2. Investigate synthesis of 2,4-diamino-5-phenyl pyrimidine with an amino group at 
position 6 and elaboration of the structure with various side-chains. 
 



















3.  Results & Discussion 
 
3.1 El-Hamamsy's research 
 
The aim of this project is to develop a selective DHFR inhibitor of M. tuberculosis. The 
idea has come from previous research by El-Hamamsy,45 who successfully designed a 
lead compound (Figure 19) with the main characteristics of an inhibitor of DHFR in M. 
tuberculosis. The design of this compound (Figure 21) was a result of studying the 
binding site of DHFR in M. tuberculosis.45 
 








Figure 21: El-Hamamsy lead compound.        
 
Studying the binding site of DHFR in M. tuberculosis showed significant features, 
including: the glycerol pocket in the binding site of the DHFR enzyme and how this 
glycerol is binding to the amino acids in the same site of DHFR via three hydroxyl 
groups. The lead compound that was synthesised by El-Hamamsy (Figure 21) consists 
of a 2,4-diaminopyrimidine moiety, which is known to be selective and potent for a 
DHFR inhibitor.45  
 
Because of the waxy layer in the cell wall of M. tuberculosis, the penetration of the 
targeted compound will be difficult. To overcome the penetration problem, the 
introduction of a lipophilic group such as phenyl group at position 5 of the pyrimidine 
ring was incorporated by El-Hamamsy, the phenyl group will enhance the lipophilicity 
of the compound and facilitate the diffusion through the waxy layer of M. tuberculosis. 
Another benefit from the introduction of the phenyl group at position 5 of the 




To enhance the binding affinity to the glycerol pocket in the M. tuberculosis DHFR 
binding site, the trihydroxypentyl side chain was synthesised by El-Hamamsy, and 
linked to the pyrimidine ring at position 6 (Figure 21). The three hydroxyl groups bind 
to the amino-acids in the binding site the same way as the glycerol does by forming 
hydrogen bonds.45  
 
El-Hamamsy had done modelling studies for the compound (Figure 21) and the crystal 
structure of DHFR in M. tuberculosis has shown that the perfect linker between the 2,4-
diamino-5-phenylpyrimidine and the 3,4,5-trihydroxypentyl that mimics the glycerol 
unit in DHFR binding site of M. tuberculosis, is a two carbon chain (-CH2CH2) linked 
to position 6 of the pyrimidine ring.45 
 
3.1.2 El-Hamamsy's target compounds 
 
El-Hamamsy synthesised a series of 2,4-diaminopyrimidines (1)–(6) (Figure 22-26)  
with a two carbon linker to the glycerol-mimicking triol (3,4,5-trihydroxypentyl) at 
position 6 of the pyrimidine ring; the 2,4-diaminopyrimidine unit in these compounds 
carried an aryl substituent at position 5. These features were based on structure-based 
design. 
 
El-Hamamsy designed a lead compound after modelling the location of the DHFR 
binding site of M. tuberculosis (Figure 22), finding the stereochemistry of the designed 
compounds (1)–(6) is an important factor for the 3,4,5-trihydroxy unit to mimic the 
glycerol molecule in the binding site, R configuration at C-3 and an S configuration at 
C-4 of the secondary alcohol of the 3,4,5-trihydroxypentyl unit were expected to give 
the same binding properties of the original glycerol molecule in the binding site of 
DHFR in M. tuberculosis (1).45 
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El-Hamamsy also designed other derivatives by changing the configuration at C-3 to an 
S configuration with the same length of the linker (-CH2CH2), to test if the design 
approach was valid (Figure 23).45 
 
                                                                                                     
 
El-Hamamsy also investigated the importance of the 3,4,5-trihydroxy groups in the lead 
compound (Figure 19), replacing it by introducing a 6-(5-hydroxypentyl) on the 
pyrimidine ring instead of 3,4,5-trihydroxypentyl (3) (Figure 24), which means there is 
no hydrogen bonding between the glycerol mimic unit (6-(5-hydroxypentyl) and the 
amino acids (Trp22, Asp27 and Gln28) that were shown in the glycerol binding site of 
the DHFR.45 
   




Another modification designed by El-Hamamsy, changed the orientation of the 3,4,5-
trihydroxypentyl group directed to the pyrimidine ring with a shorter carbon-chain 
length (4) (Figure 25).45  









Figure 25: 6-(1S,2R)-1,2,3-trihydroxypropyl compound.                   
 
El-Hamamsy also designed other 5-phenyl-2,4-diaminopyrimidine compounds, one by 
replacing the 3,4,5-trihydroxypentyl group by a benzyl group (5) (Figure 26), which 
might have an unfavourable interaction in the hydrogen bonding environment of the 
glycerol-binding pocket in the DHFR binding site of M. tuberculosis.45 
 
                                     
 
The other compounds that were designed removed any group that would occupy the 
glycerol pocket (6) (Figure 27).45 
 










3.1.3 El-Hamamsy's synthetic strategy for 5-phenyl-2,4-diaminopyrimidne 
compounds 
 
El-Hamamsy's synthetic strategy for the 2,4-diaminopyrimidine unit in compounds (1- 
6) was the condensation of a substituted enol ether, appropriate for synthesis of each of 
these compounds (1-6), with guanidine. The enol ethers (7) were prepared by 
methylating the α-acylphenylacetonitrile (8) that resulted from the reaction of an Ar-
substituted phenylacetonitrile (9) with the appropriate ester (10) for each compound's 
synthesis (Scheme 6).45 
 
                                       
       
 
3.1.4 El-Hamamsy's synthetic strategy for 3, 4, 5-trihydroxypentyl compounds 
 
El-Hamamsy's plan was synthesis of two building blocks, the 2,4-diaminopyrimidine 
and the 3,4,5-trihydroxypentyl group, followed by linking the two units. Synthesis of 
the 3,4,5-trihydroxypentyl unit from the ester (15), started with acetonide protection of 
the cis 3-OH and 4-OH of arabinose (11), followed by oxidation cleavage of the (C-1, 
C-2) bond with periodate to give the protected L-erythrose (12) (Scheme 7).45 
 
To achieve the two carbon chain extension at position 6 for compounds (1-6), El-
Hamamsy managed to apply Wittig reaction of the aldehyde with 
ethyltriphenylphosphoranylidineacetate to afford the stereoisomeric α, β -unsaturated 
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esters (13), (14). These isomers were readily separated by chromatography but it was 
not necessary as the hydrogenation of the mixture gave the saturated ester (15) 
quantitatively (Scheme 7).45 
 
      
 
 
3.1.5 Synthetic route to target compound (1) 
 
In order to synthesize (1), El-Hamamsy investigated many protecting groups for the 
primary alcohol (15), finally benzylation was chosen. Benzylating the hydroxyl group to 
give the fully protected ester  (16), was affected by deprotonation with lithium 
bis(trimethylsilyl)amide and alkylation with benzyl bromide. The α-
acylphenylacetonitrile (17) was generated from reaction of the phenylacetonitrile and 
the protected ester (16) with lithium bis(trimethylsilyl)amide. This was followed by 
methylation with diazomethane to give the enol ether (18) (as a mixture of geometrical 
isomers). Condensation of this isomeric mixture with guanidine gave the required 2,4-
diaminopyrimidine (19). After joining the required units, El-Hamamsy had investigated 
many ways to remove the protecting groups, such as the removal of the acetonide with 
aqueous trifluoroacetic acid to give compound (20). Also El-Hamamsy investigated the 
removal of the benzyl group by catalytic hydrogenation with chloroform, unfortunately, 
it failed to remove the benzyl group. El-Hamamsy managed to debenzylate (1) after 
trying different methods. The reduction of the O-benzyl with sodium in ammonia 
succeeded but because it is not applicable for the halogen-substituted compounds, which 
was El-Hamamsy's intention, El-Hamamsy applied the reaction with the Lewis acid 




            
 
3.1.6 Synthetic route to target compound (2) 
 
El-Hamamsy obtained (2) by following the same strategy as compound (1) but by 
starting with diethyl trans-R,R-tartrate (21) followed by acetonide protection (22), then 
reduction with lithium aluminium hydride to obtain the C-2 symmetric diol (23). The 
mono-protection of (23) was developed  with sodium hydride in dimethylformamide 
(DMF) followed by benzyl chloride alkylation protection to give (24). This was then 
oxidised by pyridinium chlorochromate to give the aldehyde (25), then the Wittig 
reaction was applied by condensing the aldehyde (25) with ethyl 
triphenylphosphoranylidineacetate to give again the chain-extended α,-β-unsaturated 
ester (26). Then a hydrogenation in the presence of palladium reduced the alkene (26) to 
form (27). This was treated the same way as (Scheme 1) to give (29), acid hydrolysis 
removed the acetonide to give (31) and iron (III) chloride carried out the debenzylation 







3.1.7 Synthetic route to target compound (3) 
 
Formation of (3), in which the carbon chain was shortened, followed the same 
condensation with guanidine, methylation with diazomethane then the deprotection 
strategy, starting from condensation of L-erythrolactone (32) with phenylacetonitrile to 
give (33), then methylation to give the enol ether (34), which then condensed the same 
way with guanidine. The acetonide was removed in the same way in aqueous acid  to 
give (3) (Scheme 10).45 
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3.1.8 Synthetic route to target compound (4) 
 
The lactone strategy was also applied to form (4) a 6-(5-hydroxypentyl)pyrimidine-2,4-
diamine. Condensation of a lactone (36) with lithium bis(trimethylsilyl)amide and 
phenylacetonitrile gave (37) in very low yield; then methylation of (38) with 
diazomethane and condensation with guanidine gave (4) (Scheme 11) and no 





























3.1.9 Synthetic route to target compounds (5) and (6) 
 
The synthesis of the 2,4-diaminopyrimidines (5) and (6) with no alcohol at position 6 
was approached by the same strategy as before (Scheme 6) with condensation and then 
methylation.45 
 




Acylation of phenylacetonitrile with ethyl 2-phenylpropanoate (39) gave (40), which 
was then methylated with diazomethane to give (41). The usual way of the condensation 
with guanidine formed (5), while (6) was formed by acylating phenylacetonitrile with 




3.1.10 El-Hamamsy's biological studies and conclusion 
 
After designing and synthesising these series of compounds (1-6), El-Hamamsy had 
carried out indirect biological studies to test these compounds, as testing these 
compounds directly against M. tuberculosis directly requires biosafety level 3 
procedures. El-Hamamsy evaluated the inhibitory effect of these compounds against the 
growth of yeasts containing human and M. tuberculosis DHFRs. Only compound (1) 
has selectivity and activity against M. tuberculosis DHFR, while the others varied from 
modest to no activity. El-Hamamsy found that the configuration is critical for 
selectivity. The presence of the secondary alcohol at position 6 of the pyrimidine ring is 
necessary for binding to the glycerol-binding pocket. The length of the linker is also 
critical as compound (3) with shorter extension decreased the activity against M. 
tuberculosis DHFR. Compound (1) was also shown to be the most selective by 
modelling; it binds in the same mode as methotrexate in the binding site.45  
El-Hamamsy had achieved the best conformation for the compound (1); the phenyl 
group had to be twisted by rotating it anticlockwise out of the plane. It fit well into the 
site as the rotation clockwise from the plane showed that the edge of the phenyl ring 
was pressed against the top of the enzyme very tightly.45  
 
3.2 Discussion of the current project 
 
The lead compound (1) that had been designed by El-Hamamsy is the current focus of 
this project; aiming to modify it to be more selective and more flexible at the binding 
site, the new plan is to look for other strategies to make the synthesis easier, such as 
replacing the (-CH2) of the linker that is adjacent to the pyrimidine ring with an oxygen, 
nitrogen or sulfur. Oxygen will sterically mimic CH2 closely, whereas an NH will be sp2 
hybridised and introduce some rigidity, sulfur is slightly larger than CH2 and will locate 









3.2.1 Synthesis of 5-phenyl-2,4-diaminopyrimidine motif 
     
3.2.1.1 Diaminopyrimidines role  
 
As our compound is one of the 2,4-diaminopyrimidine derivatives, there are many 
studies that have focused on their structures, synthesis and their potency against many 
diseases that are caused by specific microorganisms or tumours.55  
 
Many natural and synthetic biomolecules have interesting properties because of the 
pyrimidine ring in their structures, which plays an important structural role. These 
biomolecules are the nucleotide bases components in DNA and RNA of living cells; 
vitamins; coenzymes; and also some drugs, such as sulfadiazine and fluorouracil.55 
 
3.2.1.2 Diaminopyrimidines classifications and structures 
 
Hitchings et al.56 reported that diaminopyrimidines are classified into two types in terms 
of potency and structure according to studies that focused on folic acid antagonists in 
the growth of Lactobacillus casei: the substituted diaminopyrimidines at position 5 and 
the unsubstituted diaminopyrimidines. The substituted diaminopyrimidines are one 
hundred times more potent than the unsubstituted diaminopyrimidines.56 One of the 
properties of the diaminopyrimidine structures is that diaminopyrimidines have 
structural and geometrical similarities to the folinic acid and its metabolites, these 
similarities include: the disubstituted pyrimidine and the benzene rings. Any 
modification on the chemical structure of the diaminopyrimidine may change their 
functions and make them specific against particular species and tissues. This is the main 
way for finding a treatment target.56 
 
Studying the exact chemical structure of the diaminopyrimidines and their affinity to the 
receptors on the organisms has led to knowing certain conditions and specifications that 
play a key role on the modifications of the substituents on the pyrimidine ring at 




                                      
                                                    
Another property for aminopyrimidine and its derivatives is that they are able to form 
stable hydrogen bonds through the amine groups on the pyrimidine ring, this hydrogen 
bonding is important in molecular recognition, especially in biological systems.55 
 
3.2.1.3 Diaminopyrimidine derivatives studies  
 
A 2-aminopyrimidine and its derivatives, have a broad spectrum activity against many 
microorganisms. The organic synthesis of these compounds has been of interest for 
years, and many studies have shown different methods for the synthesis of these 
compounds, and this was apparent in the introduction of the Glivec® (Imatinib) (Figure 
29) in 1995 as 2- aminopyrimidine kinase inhibitor.55 
 
                                        
 
The introduction of Glivec® was one example for many studies that found out about the 
uses of the 2,4- diaminopyrimidines as antitumour.55 
 
Hitchings et al.56 introduced a suggestion according to the similarities in the chemical 
structure between the substituted diaminopyrimidines at position 5 (47) and the 
antimalarial biguanides (48) (Figure 30), that the 5-substituted diaminopyrimaidine 












Figure 30: 47; 5-substituted 2,4-diaminopyrimidine; 48: Biguanide.  
 
Hitchings et al.56 also investigated how the modified substituents at position 5, 6 in the 
diaminopyrimidines will show some activity against Streptococcus faecalis and 
Lactobacillus casiae as they inhibit the folic acid or folinic acid, and it has been found 
that 5-phenoxy-2,4-diaminopyrimidine (Figure 31) are more active as folic acid 
antagonist in Lactobacillus ceasie. Also some studies have shown that the 
diaminopyrimidines have some activity against Plasmodia and Taxoplasma because 
they are antimetabolites of the folic acid.56 
 
                                    
 
Other diaminopyrimidine derivatives that have been found with some antibacterial 
effects are diaminopyrimidine substituted at position 6; they have shown some activity 
against the DHFR in M. leprae and M. sp. 607 but there is no mycobacterial cell growth 
inhibition and this was an inspiration to study the fused bicyclic pyrimidine system 
against the Mycobacterium species such as M. sp. 607, for example, fused bicyclic 
pyrimidines and 2,4-diamino-5-methyl-6-alkylquinazolines (49). Compound (49) has 
shown moderate to strong growth inhibition of M. sp. 607. By investigating different 
2,4-diamino-5-methyl-6-alkylquinazolines, those investigators found out that the 
activity increased with alkyl groups such as propyl quinazoline and 6- propyl analogues, 
and it also (49) has a synergistic effect against M. sp. 607 with  dapsone (bis(4-








For antimicrobial activities, some derivatives of 5-benzyl-2,4-diaminopyrimidine have 
been investigated by Roth et al.59 Two interesting findings came from that study. First, 
the unsubstituted-6-diaminopyrimidines showed the highest activity. Second, the 
substituted benzyl at position 5 of the diaminopyrimidines with one or more alkoxy 
groups at meta and para positions (51) (Figure 33) showed a strong activity against 
gram positive organisms and some activity against several gram negative organisms.59 







Figure 33: Substituted benzyl at position 5 of the diaminopyrimidines with one or more alkoxy





The aim of some studies was looking for more substituted 5-benzyl-2,4-
diarninopyrimidines to broaden the activity spectrum against gram negative bacteria. 
Some of the results of these studies was the synthesis of  p- and m-methoxy, and halo 
groups on 5 benzyldiaminopyrimidines (52) (Figure 34), these showed high activity 
against Proteus vulgaris. This early discovery led to more synthesis of different alkoxy 





                
 
In 1999 there was the discovery of the novel quinzalonediamines as DHFR inhibitor. 
Their structures are characterised by a 2,4-diaminopyrimidine ring with a lipophilic 
tricyclic group at position 6. They showed high activity against some bacteria, for 
example, (53) is highly effective against M. avium DHFR and (54) is active against 
Mycobacterium avium, Toxoplasma gondii and Pneumocystis carnii (Figure 35).60  
 




Robson et al.61 studied 12 novel 2,4-diamino-5-aryl-6-ethyl pyrimidines (Figure 36) and 
assessed these compounds to be non-classical inhibitors of Pneumocystis carinii and 
Toxoplasma gondii DHFRs.61 
                                                   




Some studies in the hormones field have found that the 2,4-diaminopyrimidines 
derivatives are active against Ghrelin, which is a hormone in the stomach and 
hypothalamus that causes obesity because it stimulates the hunger centre, which leads to 
more food intake. The study of the synthesis of different substituents has been carried 
by Serby et al.62 In addition it has been found that the DHFR inhibition is much higher 
and stronger than Ghrelin hormone inhibition.62 
 
3.2.1.4 Common methods for synthesis of 2,4-diaminopyrimidines       
 
There are many different strategies that have been reported for the synthesis of different 
2,4-diaminopyrimidine derivatives. It has been reported that the primary amino group at 
position 2 can be introduced by using guanidine as the one-carbon fragment. Guanidine 
supplies the 2-NH2, the 2-C and the two ring nitrogens. The other primary amino group 
at position 4 can be introduced by using a nitrile or dinitrile in the three-carbon 
fragments. Scheme 13 shows one of the studies carried out by Russell et al,63 a 
condensation of β-aldehydonitriles (55) with guanidine. This, however, gave 2-amino-4-
benzyl-1,3,5-triazine (56), through direct attack of the guanidine on the electrophilic 
nitrile, followed by a transformylation (57) and cyclisation (58). This problem was 
overcome by methylating the β-aldehydonitrile (59) with diazomethane to convert it to 
the enol ether (60). Condensation of the enol-ether with guanidine (61) then gave 2,4-
diaminopyrimidine derivatives (62) (Scheme 13). This suggests that the condensation of 
enol ether with guanidine is easier and takes place by attack of the conjugate 







Another strategy for the preparation of 2,4-diamino-5-phenylpyrimidine derivatives by 
Elion et al.64 is useing an ester instead of a nitrile (Scheme 14). For example, -
formylphenylacetic esters (63), if it condensed with guanidine will give 2-amino-4-
hydroxypyrimidine (64). Chlorination by phosphorus oxychloride (65) followed by 
treatment with ammonia gave the expected 2,4-diaminopyrimidine (66). Analogously, 
purinones (67) can be converted to mercaptopurines (68) with phosphorus pentalsulfide, 
these can then be methylated (69) and treated with ammonia to give aminopurines (70) 
(Scheme 14).64 The problem with these two pathways, however, was the very low 
yields.  
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Another way to synthesize the 2,4-diaminopyrimidine core was demonstrated by Serby 
et al.62 They started with acylation of 4-nitrophenylacetonitrile or 4-
cyanophenylacetonitrile (71) with an acid chloride (72) to give an aryl-α-ketonitriles 
(73); then (73) reacted with either trimethylsilyldiazomethane or diazomethane in 
diethyl ether to give enol ethers (74). By treating (74) with guanidine and removing 
methanol, the 2,4-diaminopyrimidine (75) was formed (Scheme 15).62 
 
                          
 
 
Some modifications have been done for compound (75) on the same study by using 
different kinds of groups by replacing the X group on (75) to test them against the 
growth hormone Ghrelin; and the result was that (75) still possesses the highest activity 
against DHFR.62 
 
Koroleva et al.55 have reviewed the literature on the syntheses of 2-aminopyrimidines. 
They identified two types of route to these compounds, condensation reactions forming 
the ring from a reagent carrying the 2-NH2 (or generating the 2-NH2 during the 
condensation) and SNAr reactions in which a leaving group at the 2-position of a pre-








3.2.1.5 Different condensation method with guanidine 
 
There are different methods of pyrimidine ring condensation, depending on the nature 
of the moieties. Compounds with β-dicarbonyl, such as β-keto esters, and β-keto 
nitriles, can react with any nucleophile in polar solvent in the presence of a condensing 
agent such as guanidine. This reaction when it is  followed by removal of water or 
methanol, gives a condensed pyrimidine ring.57 
 
In the 1980s, mono- and di-β-sulfonyl derivatives of α,-β-unsaturated ketones were 
discovered as starting materials for synthesis of 2-aminopyrimidines. These compounds 
contain two reactive sites for nucleophilic reaction at C -1 and C -3. The reactions of 
sulfanyl α,β-enones with guanidine afford the corresponding 2-aminopyrimidines 
(Scheme 16).57  
                                           
                            
 
Also, another method for the condensation that had been reported is condensation  of α-
cyanoketene S,S-acetals with guanidine and potassium carbonate to give 2,4-
diaminopyrimidines (Scheme 17).57 
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3.2.1.6 Synthetic strategy of 2,4-diaminopyrimidne motif by condensation with 
guanidine 
 
Our work in in this area began with planning a synthetic strategy of 2,4-
diaminopyrimidine motif. Many studies have reported that the condensation of -
formylphenylacetic esters with a group at the ortho position leads to unsuccessful 
reaction.65 The reason might be the enolisation and the acidity of these β-carbonyl 
derivatives. Successful condensation of the enol-ethers with guanidine has, however, 
been reported and proved by Rupe.66 He introduced the synthesis of 2-amino-5-
phenylpyrimidine as shown in Scheme 18. This approach was therefore adopted in the 
synthesis of the 2,4-diaminopyrimidine derivatives. 
 
 
                        
 
Scheme 19 shows one of the suggested plans, the retrosynthetic planning for the first 
target compound (76). This target is formed by deprotection of (77). This key 
compound is formed from the chloropyrimidinediamine (78) and the masked triol unit 





In the present work, to start with both plans the first steps were the same. The first 
attempt to synthesise the 2,4-diaminopyrimidine derivative therefore began by treating 
guanidine hydrochloride with tert-butoxide to form the free base and make it a better 
nucleophile. This was then treated with diethyl phenylmalonate (80), which is 
commercially available (Scheme 20).  
 
                             
 
 
The reaction was monitored with thin layer chromatography (TLC) over five hours 
without any progress observed. The reaction was repeated using two equivalents of the 
potassium tert-butoxide but the result was the same. Basford67 carried out the same 
reaction using sodium methoxide in methanol under reflux. Using his conditions, the  
reaction was therefore repeated with sodium methoxide under reflux for three hours to 
give (81) in 46% yield (Scheme 21).67 The reason for this difference in outcome with 









3.2.2.2 Halogenation of carbonyl groups 2-Amino-5-phenyltetrahydropyrimidine-
4,6-dione / 2-Amino-5-phenylpyrimidine-2,4-diol of (81) by phosphorus 
oxybromide and phosphorus oxychloride 
 
In order to introduce an amino group at position 4 of the pyrimidine ring, the site should 
be susceptible to nucleophilic attack. Firstly, the synthesis of 2-amino-4,6-dibromo-5-
phenylpyrimidine (82) was attempted, as bromide is an excellent leaving group for the 
next step (displacement with an amine). However, treatment of (81) with phosphorus 
oxybromide at reflux gave a crude mixture of (82) and products with bromine 
introduced electrophilically into the benzene ring. Chloride is a weaker leaving group 
than bromine but may be satisfactory for the next step. Halogenation of the carbonyl 
groups was carried out by treating compound (81) with phosphorus oxychloride under 






3.2.2.3 Aminative dehalogenation of 4,6-dichloro-5-phenylpyrimidin-2-amine  (83) 
with benzylamine 
 
There are many ways to substitute the chlorine at position 4 with an amino group. 
However, this kind of reaction needs harsh conditions, which limits this to strongly 
nucleophilic alkylamines and anilines. A direct method for the aminative 
dehalogenation of (83) is by dissolving the chloropyrimidine in ethanol and introducing 
ammonia gas into the ethanolic solution at 0°C until saturation; the mixture is heated for 
five hours at 100°C. This method, however, is said to result in low yields, owing to the 
volatility of the ammonia.67 Another method of using ammonia has been employed by 
Basford,67 by heating the compound with aqueous ammonia in a sealed tube at 140-
150°C for twelve hours. Because of the harsh conditions required and the low yield that 
have been reported for this method, the next step was to look at other procedures that 
could give the wanted amino group under mild conditions with reasonable yields. 
Basford67 has also displaced one of the chlorines of (83) with the involatile arylamine; 
4-chloroaniline at reflux in acetic acid for one hour.67 This method inspired the idea of 
treating (83) with benzylamine under the same conditions, to introduce a 4-benzylamino 
group, which could later be debenzylated. Treatment of the dichloropyrimidine (83) 
with benzylamine gave (86) in 62% yield (Scheme 21). There was no evidence of 
formation of a 4,6-bis(benzylamino)pyrimidine, which shows that displacement of the 
second chlorine is more difficult. 
 
3.2.2.4 Amination of aryl halides 
 
The traditional method for the conversion of an aryl halide to an aryl amine uses 
palladium, copper or nickel in presence of ligand. Palladium-catalysed reactions are of 
great interest in pharmaceutical and chemical synthetic research68 (Scheme 22). 
 






                                        
                
 
 
Amination of aryl halides can be done in the absence of a palladium catalyst. Generally, 
amination of aryl halides in the presence or absence of palladium catalyst, nucleophilic 
amine and appropriate base are essential for the reaction. Scheme 23 shows two 
pathways for the amination of aryl  halides, both of them in presence of a nucleophilic 
amine and base.  
 




3.2.2.4.1 Attempts to remove the benzyl group of 4-benzylamino-6-chloro-5-
phenylpyrimidine-2-amine  (86) 
 
In order to remove the benzyl group of  (86), it was heated with hydrogen bromide in 
acetic acid for two hours. NMR showed that there was no reaction but only the starting 
material remained. The reaction was therefore repeated overnight, for a longer time, but 
the result was the same.  
 
The next trial used the most direct and common method for removal of a benzyl group. 
Hydrogenation of (86) with hydrogen/ palladium in methanol was carried out overnight 
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but this also failed to remove the benzyl group. . The ease of cleavage of benzyl 
protecting groups by hydrogenation correlates with the leaving group ability of the 
heteroatom attached to the CH2. Thus benzyl esters and Cbz protecting groups are 
readily cleaved by hydrogenation (and with HBr), benzyl ethers are less reactive and 
benzylamines require forcing conditions (e.g. high pressure69or acidic solvent or transfer 
hydrogenation at high temperature70), if they react at all. 
 
3.2.2.5 Aminative dehalogenation of 4,6-dichloro-5-phenylpyrimidin-2-amine (83)  
carrying a 4-methoxy benzyl (PMB)-protected amine instead of a benzyl amine         
 
Clearly the protecting group needs to be more easily removed and 4-methoxybenzyl 
(PMB) was investigated next. This 4-methoxybenzyl (PMB) group should be removed 
more easily than benzyl by treatment with acid such as hydrogen bromide, other 
methods that could remove the 4-methoxybenzyl (PMB) group are hydrogenation and 
oxidation.68 However, 4-methoxybenzylamine is slightly more nucleophilic than 
benzylamine and the reaction with (83) resulted in a mixture of the desired (84) 
(containing one 4-methoxybenzyl (PMB)-NH- group) and (85) in which both chlorines 
have been substituted. These were successfully separated by column chromatography to 
give (84) in 68% yield (Scheme 21).  
 
3.2.2.6 Cleavage of 4-methoxy benzyl (PMB) group of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) 
 
Hydrogenolysis with palladium is also known as a good method for the 4-methoxy 
benzyl (PMB) cleavage. Other reductive methods using reducing agents such as sodium 
cyanoborohydride.71 may also be effective, but have been quite rarely studied.  
 
Another way is treating the 4-methoxy benzyl (PMB) compound with an acid such as 
acetic acid in high temperature, trifluoroacetic acid in dichloromethane, or by using 
Lewis acids such as aluminium chloride or boron trifluoride.71 
 
The third method is the oxidation method. The common oxidative agents used in this 
kind of reaction are 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and ceric 
ammonium nitrate (CAN) under neutral conditions. Oxidation by 2,3-dichloro-5,6-
65 
 
dicyano-1,4-benzoquinone (DDQ) should normally happen in dichloromethane with 
small amounts of water or methanol. Adding water or methanol to the solvent system 
helps with the solubility, as 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) is 
insoluble in dichloromethane. The reaction forms a charge-transfer complex between 
the electron donating ring of the 4-methoxybenzyl (PMB) and the electron accepting 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone  (DDQ)  resulting in formation of p-






3.2.2.7 Attempts to remove the 4-methoxy benzyl (PMB) group of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) 
 
In order to remove the 4-methoxy benzyl (PMB) group, many attempts were made to 
test which method is most effective to cleave the PMB group of (84), after replacing the 
chloro atom in position 6 with the amino derivatives. 
 
Attempt 1: Removal of 4-methoxy benzyl (PMB) of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) by acid 
 
The first attempt was by treating compound (84) with hydrogen bromide in acetic acid 
under reflux. Even though the colour had changed to red in 5 hours, thin layer 
chromatography (TLC) and NMR showed that no reaction happened.  
 
Another trial was with another acid, the reaction of (84) with sulfuric acid for 16 hours. 
This reaction also failed to remove the 4-methoxy benzyl (PMB) group and the starting 




Attempt 2:  Removal of 4-methoxy benzyl (PMB) of (84) by hydrogenation 
 
Another attempt for 4-methoxy benzyl (PMB) removal was by transfer hydrogenation. 
This reaction was catalysed by palladium on carbon and ammonium formate in 
methanol, refluxed under argon. Thin layer chromatography (TLC) again showed that 
no reaction happened. The reaction was left then for a longer time, for another sixteen 
hours, thin layer chromatography (TLC) was the same with no trace of any reaction. 
The reaction mixture was filtered through Celite® and washed with methanol. NMR 
showed the recovered starting material (84).  
 
Attempt 3:  Removal of 4-methoxy benzyl (PMB) of (84) by oxidation 
 
An oxidation with ceric ammonium nitrate (CAN) to remove the 4-methoxy benzyl 
(PMB) group was investigated. Compound (86) with ceric ammonium nitrate (CAN) in 
a solvent system 3:1 (acetonitrile /water), (to ensure the solubility), were mixed together 
at room temperature, following the literature,71 but unfortunately the reaction failed. 
 
Another oxidising agent investigated was 2,3-dichloro-5,6-dicyanobenzoquinone 
(DDQ). Compound (84) was treated with one equivalent of 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone  (DDQ) in a dichloromethane / methanol solvent system at room 
temperature for two days, changing the colour of the reaction mixture from green to 
partially red, thin layer chromatography (TLC) showed that a reaction had happened. 
The NMR spectrum showed that the reaction had gone half-way, with the 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (DDQ) only being reduced to the semiquinone radical or 
quinone / hydroquinone charge-transfer complex. Thus  an  extra equivalent of 2,3-
dichloro-5,6-dicyano-1,4-benzoquinone  (DDQ) was added and the reaction was left for 
another day. The colour of the reaction mixture changed completely to red. NMR 
showed that the wanted compound (87) formed. The oxidation with 2,3-dichloro-5,6-
dicyano-1,4-benzoquinone (DDQ) successfully removed the 4-methoxy benzyl (PMB) 
group. Washing (87) with diethyl ether gave a reasonable yield of 50% (Scheme 25). 
This approach was the plan for the 4-methoxy benzyl (PMB) removal after replacing the 
chlorine atom in position 6 of (84) (Scheme 25).  




              
    
 
 
3.2.2.8 Replacement of chlorine atom at position 6 of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) with aromatic amine 
 
For compound (84), replacement of the chlorine atom at position 6 was very 
challenging, the main idea is to replace the chlorine atom with an amine, and this should 
be done by treating the compound (84) with benzyl amine,  followed by a removal step 
for the benzyl group. Then, the removal of the 4-methoxy benzyl (PMB) group at 
position 4, which had been investigated, followed with the 2,3-dichloro-5,6-dicyano-
1,4-benzoquinone  (DDQ) oxidation. The idea of removing the 4-methoxy benzyl 
(PMB) group and the benzyl amine in one step would save time. 
 
Because of the electrophilicity of the compound (84), with only one halogen atom at 
position 6 is decreased, so the reaction with an amine such as benzyl amine (88) will 
need a forcing condition and longer time. The compound (84) was treated with 
benzylamine and acetic acid under reflux at 130°C. The reaction was monitored and 
checked by thin layer chromatography (TLC) every three hours, but unfortunately no 
reaction happened. The next day extra equivalents of the benzyl amine were added but 
the result was the same (Scheme 26). 
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3.2.2.9 Replacement of chlorine atom at position 6 of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) with aliphatic amine 
instead of aromatic amine 
 
The target compounds are pyrimidine-2,4,6-triamines, so the 4-(4-
methoxybenzyl)amino group and the 6-(hydroxyalkylamino) group could be introduced 
in either of two orders. Changing the order of reaction, the 4-(4-methoxybenzyl)amino 
group was introduced by reaction of the dichloropyrimidine with 4-
methoxybenzylamine, The second chlorine is more difficult to displace (owing to the 
mesomeric electron-donating properties of the 4-PMBNH- group), so selective reaction 
is possible. Now the latter chlorine (in intermediate (84)) was displaced under forcing 
conditions with a series of aminoalcohols; in these the amine is much more nucleophilic 
than the alcohol and protection of the alcohol was unnecessary. 
 
3.2.2.10 Dehalogenation of chlorine at position 6 of 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine (84) with 4-aminobutanol 
 
Changing the plan to replacement of the chlorine at position 6 of compound (84) with 





Several attempts have been made to investigate the reaction with 4-aminobutanol. First, 
compound (84) was treated with 4-aminobutanol in ethanol in the presence of the base 
potassium carbonate at 78°C, overnight, no reaction occured. 
 
The same problem with the poor electrophilicity of compound (84) had come to mind. 
Changing the reaction conditions with 4-aminobutanol was the next plan by repeating 
the reaction of (84) and 4-aminobutanol in the presence of potassium carbonate in 
different solvents with a higher boiling point. The reaction was done in 2-
methoxyethanol at 130°C. Thin layer chromatography (TLC) showed a new spot in two 
days; the NMR spectrum of the crude mixture showed new compound was formed. 
However, an aqueous work-up and NMR spectroscopy revealed that the 2-
methoxyethanol had reacted as the nucleophile to displace the chlorine, forming 
compound (94) (Scheme 27). This was shown by the presence of a singlet for the 






     
 
 
3.2.2.11 Testing the 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) oxidation to 
remove the 4-methoxy benzyl (PMB) after the methoxyethanol reaction (94) 
 
Compound (94) was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone  (DDQ) in 
dichloromethane / methanol mixture; the 4-methoxybenzyl (PMB) group was 
successfully removed to give (97) in a good yield. This was a proof that removal of 






3.2.2.12 Bromination of carbonyl group of 2-amino-5-phenyltetrahydropyrimidine-
4,6-dione / 2-amino-5-phenylpyrimidine-2,4-diol (81) with PBr3 
 
                           
 
 
The reaction of compound (84) with 4-aminobutanol was difficult. Changing the 
solvents was not helpful with the reaction, so replacement of the chloro atom with a 
bromo was adopted as the new plan. Bromine is a better leaving group, which should 
ease the reaction at milder conditions in a shorter time as well. The first attempt to 
brominate the carbonyl group of compound (81) with phosphorus oxybromide failed, so 
changing the brominating reagent was investigated. The chosen brominating agent was 
phosphorus tribromide. Dicarbonyl compound (81) was treated with phosphorus 
tribromide under reflux for sixteen hours to give the compound 4,6-dibromo-5-
phenylpyrimidin-2-amine (89) (Scheme 28) in a very good yield of 86%. 
 
3.2.2.13 Reaction of 4,6-dibromo-5-phenylpyrimidin-2-amine (89) with 4-
methoxybenzylamine 
 
The replacement of the bromine atom at position 4 with 4-methoxybenzylamine used 
the same method with the dichloro compound (83) in acetic acid and 4-
methoxybenzylamine. As the dibromo compound was expected to be much more 
reactive, the reaction was conducted at room temperature for two hours. However, no 
reaction occurred under these conditions, as shown by TLC. The temperature was raised 
in a stepwise manner. When no reaction appeared on TLC, heat was applied. The 
reaction mixture was heated at 40°C, but no reaction happened. Monitoring was 
continued every two hours with increasing temperature, first at 80°C, then at 120°C 
without any benefit. The NMR showed unidentified compounds, which meant that the 
starting material had decomposed at higher temperatures. The same experiment was 
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repeated again at lower temperature of 40°C for a longer time, but unfortunately no 
reaction happened and the starting material was recovered by column chromatography. 
 
3.2.2.14 Reaction of 4,6-dibromo-5-phenylpyrimidin-2-amine (89) with 4-
aminobutanol 
 
Another attempt of 4,6-dibromo-5-phenylpyrimidin-2-amine (89) amination was trying 
the reaction of (89) with 4-aminobutanol instead of the 4-methoxybenzylamine. 
Compound (89) was treated with 4-aminobutanol in dry dimethylformamide (DMF) 
with molecular sieves but without base under reflux at 140°C (Scheme 29). No reaction 
occurred within twenty four hours. Sodium iodide was added as a nucleophilic catalyst 
but this did not aid the reaction. The same experiment of reaction (89) with 4-
aminobutanol was repeated with adding one equivalent of potassium carbonate as a base 
but it failed as well. 
 
                     
 
 
3.2.2.15  Buchwald reaction  
 
After these attempts to replace the bromine atom of compound (89) with amino 
compounds failed by different nucleophilic displacement, a new plan was introduced: 
investigating Buchwald palladium-catalysed reaction for aminative dehalogenations. 
 
An example of palladium-catalysed aryl amine coupling with aryl halide, was reported 





         
         
 
 
Another palladium catalysed reaction was introduced by Hartwig68 but this method 
include using Josiphos-ligated palladium complex. He investigated a palladium catalytic 
system for aniline synthesis from the combination of 1.0 mol% palladium2(dpa)3 and 
5.0 mol% of biaryl phosphine ligand, five equivalents of ammonia and sodium tert-
butoxide (1.4 equiv) at 80C in a sealed tube; dioxane as solvent gave the highest 
yield.68 Application of Buchwald reaction on presence of ligand was the new plan for 
the project. 
 
The mechanism of the Buchwald reaction (Scheme 31) consists of multiple steps; the 
overall process is the cross-coupling. Presence of palladium and supportive ligand will 
enhance the cross-coupling , then an oxidative addition of an aryl halide (Ar-X) to the 
ligand and the palladium, then the nucleophilic amine is added to oxidative addition 
complex. Because of the presence of the base, deprotonation of the complex will lead to 
a reductive elimination (Scheme 30).73 Many studies about coupling of amines with aryl 
bromide have been carried out. 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) 







Palladium-catalysed reactions have been an important subject in chemical synthesis, 
with the introduction of the supportive ligands such as 2,2'-bis(diphenylphosphino)-1,1'-
binaphthyl (BINAP) and xantphos. The palladium-catalysed reaction has developed and 
improved, especially with carbon-nitrogen coupling.73  
 
The most important factors that influence palladium-catalysed reactions are: the 
palladium source, which will affect the formation of the catalysts and its effect on the 
reaction. The studies have shown that the most effective palladium catalyst is tris- 
(dibenzylidenacetone)dipalladium Pd2(dba)3 (which was the chosen palladium in our 
investigation) and palladium acetate Pd(OAc)2, especially for aryl bromides.73 
 
The second factor is the ligand used in the reaction, which always depends on the aryl 
halide substrate. Many studies have investigated different kinds of ligands; 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) showed a remarkable effectiveness for 
carbon-nitrogen coupling.73 
 
The third factor is the aryl halide substrates and the nucleophilic amines in terms of 
their electrophilicity or nucleophilicity; these factors will also affect the rate of every 
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step on this reaction such as oxidative addition, amine binding to the formed complex  
and the deprotonation by the appropriate base.73 
 
The fourth factor is the appropriate solvent. Choosing the appropriate solvent depends 
on the solubility of the substrates and the base. The most common solvents that are used 
in the palladium-catalysed reactions are toluene and dioxane; sometimes 
tetrahydrofuran (THF) and dimethylformamide (DMF), they could be used as well.73 
 
The fifth factor is the temperature applied to the reaction; temperature determines the 
rate of the cross-coupling process.73 
 
The last factor is the base. Strong bases such as sodium tert-butoxide could be used at 
room temperature; however, in some reactions, strong bases participate in unwanted 
side-reactions especially with some electrophilic and heterocyclic aromatics. Weak 
bases are also efficient in this kind of reaction and could be used at higher temperatures. 
The most common weak base that is used in the palladium-catalysed reactions is 
caesium carbonate. Caesium carbonate is mostly used in aminations with 2,2'-
bis(diphenylphosphino)-1,1'-binaphthyl (BINAP); another weak base also useful in this 
reaction is potassium carbonate. The appropriate base also will affect the rate of every 
step on the reaction. The sensitivity of the functional groups of the aryl halide and the 
amines against the base should also be considered.73  
 
From these studies, the idea was to try a Buchwald reaction to replace the bromine atom 
of compound (89) with 4-aminobutanol and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
(BINAP) ligand to fasten the reaction. Compound (89) and 4-aminobutanol were added 
to Pd2(dpa)3 and caesium carbonate  in dioxane in the presence of BINAP at 110°C but 
there was no displacement of any of the bromine atoms. 
 
After these trials with the dibromine (89) (Scheme 28) the reason for going back to the 
previous strategy with the dichlorine (84) (Scheme 27), was as the chlorine atom is 
highly electronegative, this will lower the electron density at the site of the reaction with 




3.2.2.16 Reaction of 4,6-dichloro-5-phenylpyrimidin-2-amine  (83) with 4-
aminobutanol  
 
As the reaction of compound (83) with 4-methoxybenzylamine was successful, a new 
plan was introduced and investigated, which is the reaction of compound (83) with 4-
aminobutanol first instead of 4-methoxybenzylamine. 
 
Compound (83) reacted with 4-aminobutanol and potassium carbonate as a base in 
ethanol for 16 hours; careful control of the conditions allowed replacement of only one 
chlorine atom to give compound (98) (Scheme 32) in 55% yield. 
 
         
 
3.2.2.17 Reaction of 4-((2-amino-6-chloro-5-phenylpyrimidine-4-yl)amino)butanol 
(98) with 4-methoxybenzylamine in different solvents (investigating the opposite 
way)                                                 
 
One chlorine atom of compound (83) was replaced with 4-methoxybenzylamine (84) 
and then another experiment was conducted to replace this chlorine atom of compound 
(83) with 4-aminobutanol (98). The reversal of the sequence of reactions was studied. 
Compound (98) was treated with 4-methoxybenzylamine and acetic acid at 130°C for 
two days, and no reactions occurred. Three sets of reactions were repeated and 
monitored for the same reaction again but in different solvents. The first one was in 2-
methoxyethanol, the second one was in dimethylformamide (DMF), and the third was 
without solvent. None of these conditions worked to give the compound 4-(4-
hydroxybutylamino)-6-(4-methoxybenzylamino)-5-phenylpyrimidin-2-amine (99). 
These experiments were demonstrated before realizing the reactivity of the 
methoxyethanol with the formation of (94) (Scheme 33).  
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3.2.2.18  Whether to go with the synthesis of (84) or (98)? 
 
As there still was no progress with replacement of the other chlorine atom by 4-
aminobuatnol with both (84) and (98). Further trials could continue with either (84) or 
(98). Formation of compound (84) by introducing the 4-methoxybenzylamino group 
first is much easier and quicker, as the reaction only takes two hours and the purification 
by column chromatography is much easier. 
 
3.2.2.19 Reactions of 6-chloro-4-(4-methoxybenzylamino)-5-phenylpyrimidine-2-
amine  (84) with different aminoalcohols 
 
So continuing with a new plan for the reaction with (84), four compounds of 
aminoalcohols with different carbon length were used. 
 
3.2.2.19.1 Reaction of 6-chloro-4-(4-methoxybenzylamino)-5-phenylpyrimidine-2-
amine  (84) with different aminoalcohols in dry dimethylformamide (DMF) 
 
Four sets of reactions were investigated; compound (84) was treated with one equivalent 
of 5-aminopentanol, 2-aminoethanol, 3-aminopropanol and 4-aminobutanol in dry 
dimethylformamide (DMF) under N2 at 130C. The reactions were continuously 
monitored by TLC then it was left over night. The next day, TLCs of these four 
reactions were checked and showed no reactions, four more equivalents of the 
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aminoalcohols were added to the four reactions and heating continued for more two 
days. No reactions happened; compound (84) was recovered by the aqueous work ups of 
the four reaction mixtures. 
 
3.2.2.19.2 Reactions of 6-chloro-4-(4-methoxybenzylamino)-5-phenylpyrimidine-2-
amine (84) with different aminoalcohols and potassium carbonate in dry 
dimethylformamide (DMF) 'Method 1' 
 
The same sets of experiments for compound (84) with the different aminoalcohols were 
also repeated but this time a base was added to the reactions. Two equivalents of  each 
aminoalcohol and potassium carbonate were heated in dry dimethylformamide (DMF) 
at 130C over night. The next day, TLC indicated no reaction, so four more equivalents 
of  aminoalcohols and potassium carbonate were added to each reaction mixture; these 
were heated at 130C for  two days. At this point, TLC indicated some reaction but it 
did not continue through completion. 
 
The four reactions were repeated under the same conditions but in a concentrated 
mixture with a small amount of dry dimethylformamide (DMF) to accelerate the 
reactions. Compounds (90), (91), (94) and (93) (Scheme 27) were successfully formed 
and confirmed by mass spectrometry. Purification of the four reaction mixtures was 
very difficult, as the excess of the aminoalcohols was difficult to remove from the 
formed compounds. Different methods were applied for more purifications, which were: 
several repeated column chromatography for each compound, washing the formed 
compounds with diethyl ether, and finally the normal work up with ethyl acetate/water 
have been done as well but without any benefit. These reactions gave low yields 
(varying from 10 to 20%). Moreover, these compounds were not completely pure 
because of the excess of aminoalcohols. 
 
To solve the purifications problems for these reactions, the same sets of reactions were 
repeated with smaller amounts of aminoalcohols and the base. However, despite the use 
of only three equivalents of each aminoalcohol and potassium carbonate in very small 
amounts of dry dimethylformamide (DMF) under the same conditions, the results were 
the same and impure products were obtained. The same purification issues have not 
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been solved; these impurities are hard to get rid off maybe because of the high polarity 
of the aminoalcohols, and this problem gave an idea that the solvent might be the 
problem. 
 
3.2.2.19.3 Reactions of 6-chloro-4-(4-methoxybenzylamino)-5-phenylpyrimidine-2-
amine  (88) with different aminoalcohols and potassium carbonate without solvent 
'Method 2' 
 
Reactions of compound (84) with the different aminoalcohols were repeated in the same 
conditions without solvents. The compounds were successfully formed, the purification 
by column chromatography was much easier, as the mixtures from the reactions were 
cleaner. These gave moderate yields (20 to 30%) but the products were purer 
compounds, especially with 4-aminobutanol (92) and 5-aminopentanol (93) with longer 
carbon chains, while (90) and (91) were still more difficult to purify, requiring several 
chromatography columns (Scheme 27). 
 
So the displacement of the chlorine has been shown to occur using only three 
equivalents of aminoalcohols as nucleophiles and solvents, in the presence of potassium 
carbonate as a base, although these reactions still need optimisation processes.  
 
3.2.2.20 Removal of 4-methoxy benzyl (PMB) protecting groups from compound 
(92) and (93) by 2,3-dichloro-5,6-dicyano-1,4-benzoquinone  (DDQ) oxidation 
 
As removal of 4-methoxy benzyl (PMB) group has been investigated earlier in this 
project and was successfully applied, removal of the 4-methoxy benzyl (PMB) groups 
from (92) and (93) was also investigated by applying the same conditions. 
 
Reaction of (92) and (93) with two equivalents of 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone  (DDQ) dichloromethane / methanol mixture for three days gave (95) and 
(96) in low yields, alongside impurities. thin layer chromatography (TLC) and column 
chromatography were difficult owing to the very polar nature of the target compounds. 
The compounds were identifiable by NMR and mass spectrometry. The reactions were 




3.2.3 Attempted synthesis of trihydroxy side chain: 
 
Another plan also investigated in this project at the same time was the synthesis of the 
two building blocks: 5-phenyl-2,4-diamniopyrimidine motif and the trihydroxy side 
chain. The original idea came from El-Hamamsy's study. 
  
The synthesis of the trihydroxyalkyl side-chain at position 6 of the pyrimidine ring can 
be achieved via different methods. Retrosynthetic analysis shows that these could be 
obtained from the aldehyde (101). A similar protected aldehyde had been used by El-
Hamamsy et al.45 However, a different protecting group PG was required to make the 
reaction easier (Scheme 34), as Hamamsy had experienced some difficulties in 
introducing and removing the OBn protection under mild conditions. 
 
 




El-Hamamsy et al.45 had investigated both cis- and trans-substituted 4,5-dihydro-1, 3-
dioxoles to achieve the synthesis of their diastereomeric products. For the trans series, 
the synthesis started with a diester (diethyl tartrate) (21), which is commercially 
available enantiomerically pure. The dihydroxy group of this ester reacted with 2, 2-
dimethoxypropane under acid catalysis to give the acetonide (22). The ester functional 
groups were then reduced with lithium aluminium hydride to give the C2-symmetric diol 
(23). The monoprotection of one hydroxyl group and oxidation of the other (24) gave 
the required aldehyde (Scheme 6). 
 
The corresponding cis acetonide could not be approached from the meso diethyl tartrate 
because the intermediate diol would not have been C2 symmetric and would have 
required chiral discrimination in the benzylation. Since this procedure is not practicable, 
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it was much easier to start with a sugar. The trihydroxyalkyl side-chain can be derived, 
in principle, from D-erythrose. In the literature,74 the D-erythrose 2,3-acetonide (105) is 
reported to be synthesised by condensation of L-arabinose (102) with 2,2-
dimethoxypropane and p-toluenesulfonic acid to give (103), followed by cleavage of the 
diol with sodium periodate to give the aldehyde (104). A side-product of this reaction is 
formic acid, which catalyses the intramolecular cyclisation of the aldehyde to give the 
desired erythrose (105) (Scheme 35).74 The ring-opened intermediate has the two 
exocyclic carbons differentiated as aldehyde and primary alcohol but, unfortunately, the 






3.2.3.1 Synthesis of the trihydroxy side chain starting with the ribonolactone 
 
The plan was therefore changed to start with a pentose such as D-(+)-ribonolactone 
(106), which is a commercially available lactone carrying three hydroxy groups, plus 
one masked as the lactone. These hydroxyl groups require protection to avoid unwanted 
reactions. 
 
Scheme 36 explains the new pathway, which starts with protection of the vicinal 
hydroxyl groups of ribonolactone as the acetonide. The primary hydroxyl group is then 
protected with protecting group PG1 to give the fully masked ribonolactone (107). 
Reduction of the ester then reveals a primary alcohol and a secondary alcohol in (108). 
These alcohols should then be discriminated by protection of the CH2OH with PG2 in 
(109).  Now PG1 is removed to reveal a vicinal diol, which can be cleaved oxidatively to 













































       
 
3.2.3.1.1. Acetonide protection of the hydroxyl groups of ribonolactone 
 
The protection and the deprotection procedures of the anomeric centre of chiral 
carbohydrates such as pyranose and furanose, are difficult, because it is hard to predict 
the regioselectivity on the hydroxyl groups. That is why some carbohydrates have been 
involved in spectroscopic and crystallographic studies to understand the best 
conformation for different kinds of reactions.75 
 
In practice, the 2,3-vicinal hydroxyl groups of ribonolactone can be protected by 
forming an acetal group. There are two common methods for acetonide protection of the 
vicinal groups. One is known as classical acetonation with acetone and sulfuric acid 
under high temperature for 24 hours. The other one is with 2,2-dimethoxypropane in 
dimethylformamide (DMF) and its advantages over the classical method are shorter 
time of reaction and no purification was needed.76 The classical method for the 
acetonide formation with acetone and an acid catalyst such as hydrochloric acid or 
sulphuric acid under reflux is a thermodynamic control, and the other method with 2,2-
dimethoxypropane (DMP) in dimethylformamide (DMF) is a thermokinetic. The 
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thermokinetic reaction with dimethoxypropane (DMP) also has two different ways that 
are all successful in high yields, one with dimethoxypropane (DMP) and p-
toluenesulfonic acid, and the other one is dimethoxypropane (DMP) with pyridinium p-
toluenesulfonate in dimethylformamide (DMF). Pyridinium p-toluenesulfonate is a 
weaker acid than p-toluenesulfonic acid  and is useful when acid-sensitive functional 
groups are involved such as tert-butyldimethylsilylethers,77 the acetal protecting group 
is considered a good choice for aldehydes and ketones because of its stability to base 
and the ease of its removal by acid. It is inert to nucleophilic reagents or aqueous base-
catalysed reactions and also protects the hydroxyl groups against oxidation.  
 
D-(+)-ribonolactone (106) was treated with 2,2-dimethoxypropane in the presence of 
pyridinium toluenesulfonate as acid catalyst to give ribonolactone monoacetonide76 
(112) in 62% yield (Scheme 36). 1H NMR confirmed the presence of the two methyl 
groups of the acetonide upfield. 
 




3.2.3.1.2.1 Protection of with 4-methoxy benzyl (PMB) group 
 
The next step was protecting the primary hydroxyl group of the protected ribonolactone 
3aR,6R,6aR-2,2-dimethyl-6-hydroxymethyldihydrofuro[3,4-d][1,3]dioxol-4(3H)-one 
(112). Initially, the 4-methoxybenzyl (PMB) group was investigated. 4-methoxybenzyl 
(PMB) is able to survive various reaction conditions and is easily removed by treating 
the compound with acid or by catalytic hydrogenation. The 4-methoxybenzyl (PMB) 
group is very popular and much less stable to acid than benzyl ether.77 Generation of the 
alkoxide with sodium hydride and reaction with 4-methoxybenzyl chloride78 gave (113) 
(Scheme 36) at a low yield of 20%. The presence of the 4-methoxybenzyl (PMB) group 
was shown by 1H NMR spectroscopy. Because of the low yield of the reaction and the 
sensitivity of the 4-methoxybenzyl chloride to moisture, alternative protecting groups 






3.2.3.1.2.2 Protection with tert-butyldiphenylsilylether (TBDPS) (114) 
 
Silyl ether groups include a silicon atom attached to oxygen. Their stabilities are 
different, and depends on  the substituents attached to the silyl ether, which will affect 
their stability towards acid / base hydrolysis, oxidation, reduction and column 
chromatography. The reason for the stability for most silyl ethers, such as tert-
butyldiphenylsilylether (TBDPS), is the presence of the bulky group that will increase 
the steric effect to give greater stability. Silyl ethers are easily formed from alcohols 
with the corresponding silyl chloride and base such as triethylamine. Also, its cleavage 
is easy, silyl ethers could be cleaved by fluoride ions. tert-Butyldiphenylsilylether 
(TBDPS) is the most stable to acid hydrolysis, reduction, under basic conditions 
because of its bulkiness; also it can be cleaved under acidic condition such as (acetic 
acid-tetrahydrofuran(THF)-H2O) (3:1:1); p-toluenesulfonic acid in methanol and with 
hydrogen fluoride in acetonitrile or in pyridine.77  
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tert-Butyldiphenylsilyl (TBDPS) was chosen because of its relative stability against acid 
and base hydrolysis, oxidation and reduction. The primary alcohol (112) was treated 
with tert-butyldiphenylsilyl chloride (TBDPS) and imidazole.79 Reaction of the tert-
butyldiphenylsilyl chloride (TBDPS) with the imidazole gives (TBDPS)-imidazole as 
an intermediate, which is trapped by the primary hydroxyl group. Indeed, (TBDPS)-
imidazole is selective for primary hydroxyl groups, owing to the steric bulk of the tert-
butyl group and phenyl groups. The completely protected sugar (114) was obtained in 
62% yield. The 1H NMR showed the two phenyl groups of the tert-butyldiphenylsilyl 
(TBDPS) group at the aromatic region and a single peak of the tert-butyl at an upfield 
chemical shift (Scheme 37). 
 
3.2.3.1.3 Reduction of carbonyl group of (3aR,6R,6aR)-6-((tert-
Butyldiphenylsilyloxy)methyl)-2,2-dimethyldihydrofuro[3,4-d][1,3]dioxol-3(3aH)-
one  (114) 
 
To reduce the lactone carbonyl group of compound (114), various reagents were 
considered. The most common reducing agents for carbonyls are sodium borohydride, 
lithium borohydride and lithium aluminium hydride. Sodium borohydride would not 
normally reduce esters. Lithium borohydride is selective for reduction of esters, 
aldehydes and ketones but not amides and carboxylic acids.80 
 
3.2.3.1.3.1 Reduction of (114) by lithium borohydride 
 
The ester carbonyl group at position-3 of compound (114) was reduced to the diol by 
using the reactive reducing agent lithium borohydride to give (115) in 68% yield 
(Scheme 37), 1H NMR showed the new hydroxy groups at δ 3.06.  
 
3.2.3.1.3.2  Reduction of (114) by sodium borohydride 
 
There are some factors that affect the reducing action of sodium borohydride, which are: 
the solvent, the catalyst and the activating substituents.80 In the litreature,81 a substituted 
ribonolactone with a silyl ether group was reduced by sodiumborohydride was reported. 
This milder reducing agent sodium borohydride will not usually reduce esters but only 




yl)ethanol (115) with this reagent with a higher yield of 89%. This compound is a 
lactone with an electronegative oxygen atom at the -position, which has an electron-
withdrawing inductive effect making the carbonyl group more electrophilic and more 
susceptible to sodium borohydride reduction (Scheme 37). 
 
3.2.3.1.4 Protection of the primary hydroxyl group of (R)-2-(tert-
butyldiphenylsilyloxy)-1-((4R,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-dioxolan-4-
yl)ethanol (115) attempts with different protecting groups 
  
Attempt 1: Protection of the hydroxyl group of (115) with 4-methoxy benzyl 
(PMB)     
 
The reduction of the carbonyl group gave two hydroxyl groups, one primary and one 
secondary. An attempt was made to protect the primary hydroxyl group selectively by 
treating compound (115) with 4-methoxybenzyl chloride and sodium hydride. However, 
this gave a product without the (TBDPS) group (Scheme 37). 
 
Attempt  2: Protection of the hydroxyl group of (115) with benzyl ether  
 
Another group for a hydroxyl protection is benzyl ether, they are stable to many 
aqueous acidic and basic conditions, and most reducing agents or mild oxidising agents 
at high temperatures do not affect them. Also it can be removed by catalytic 
hydrogenolysis, which is the mildest method; the catalyst of choice is  palladium on 
charcoal or palladium hydroxide. Some methods of making benzyl ethers are alkylation 
of metal alkoxide with benzyl bromide or benzyl chloride; these are the most common 
methods, since the metal alkoxide is usually generated with sodium hydride or 
potassium hydride, but these methods are not compatible with base-sensitive functional 
groups. Another method of benzyl ether formation is by using benzyl bromide in the 
presence of silver oxide (Ag2O), especially for substrates that do not survive the metal 
hydride.77 Benzylation was also attempted and compound (115) (Scheme 37) was 
treated with benzyl bromide and sodium hydride in dry dimethylformamide (DMF).78 
NMR analysis again showed the same result as for the 4-methoxybenzyl (PMB) 
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reaction, with the tert-butyldiphenylsilyl (TBDPS) group again lost. The possible 
explanation for this problem might be the use of sodium hydride, which is a source of 
hydride that may attack the silicon atom causing cleavage of the tert-butyldiphenylsilyl 
(TBDPS) group. Alternatively, the alkoxide generated as an intermediate may promote 
loss of the (TBDPS) by neighboring-group participation. 
 
Attempt 3: Protection of the hydroxy group of (115) with pivalate and benzoate 
esters  
 
Since the alkoxide may be responsible, at least in part, for the loss of the tert-
butyldiphenylsilylether (TBDPS) silyl protection, protection of the primary hydroxy 
group of (115) was investigated under conditions that do not generate alkoxides. 
Compound (115) was protected by the pivaloyl group, increased hydrolytic stability of 
the ester function is attained by pivalate, they are slower to deprotect than acetate and 
benzoate, and can be cleaved by reduction with lithium hydroxide in methanol or 
potassium carbonate in methanol under reflux.77 
 
Protection was achieved by treating (115) with triethylamine, followed by heating with 
pivolyl chloride overnight to give an oil in 54% yield, after a difficult purification by 
column chromatography (Scheme 37). Unfortunately, there is no evidence of the 
formation of (115).  
 
Another idea attempted was protection of this hydroxyl group with benzoate. It can be 
removed by tetrafluoroboric acid in methanol.77 Compound (115) was treated with 
benzoyl chloride in pyridine at room temperature for twenty four hours and caused loss 
of the tert-butyldiphenylsilylether (TBDPS) group (Scheme 37). 
 
Attempt 4: Protection of the hydroxyl group of (115) with trityl and 
diphenylmethyl groups             
 
In another strategy, attempts were made to introduce triphenylmethyl (trityl, Tr) and 
diphenylmethyl protecting groups to the primary hydroxyl of (115). Triphenylmethyl is 
a very bulky hydrophobic group, which is selective for introduction at primary 
alcohols.77 This protection is stable to base, hydride-type reducing agents and 
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nucleophiles and can easily be removed by acidic conditions because of the stability of 
the triphenylmethyl carbocation. It can be removed with protic acids in methanol such 
as acetic acid; most Lewis acids such as zinc bromide in methanol or iron(III) chloride 
can also cleave it. Some have reported that 2,3-dichloro-5,6-dicyano-1,4-benzoquinone  
(DDQ) in acetonitrile may cleave triphenylmethyl as well as liquid ammonia with Na, 
while formation of triphenylmethyl normally uses pyridine or 4-dimethylaminopyridine 
(DMAP) as solvents.77 Another known method for the protection of the hydroxyl group 
with triphenylmethyl is by treating the hydroxy compound with chlorotriphenylmethane 
in pyridine for sixteen hours at 70°C.76 Both of these methods for the triphenylmethyl 
formation would achieve their selectivity for the primary hydroxyl owing to their steric 
bulk. Triphenylmethyl ethers can be cleaved with mild acid or by hydrogenolysis, 
whereas diphenylmethyl ethers are usually cleaved by hydrogenolysis or by strong acid. 
Protection of the hydroxyl group with triphenylmethyl was attempted in sodium hydride 
and dimethylformamide (DMF) at room temperature for twenty four hours,79 but no 
reaction happened. The protecting group was changed to a diphenylmethyl ether in 
sodium hydride and dimethylformamide (DMF) for fourty eight hours. Unfortunately, 
both reactions failed and the starting material was recovered by column chromatography 
(Scheme 37). 
 
All these difficulties in the protection of the hydroxyl group in the presence of tert-
butyldiphenylsilylether (TBDPS), which are supposed to be highly stable, led to 
thinking about different strategies that El-Hamamsy45 (Scheme 6) had followed by 
using the meso-tartaric acid instead. 
 
3.2.3.2 Synthesis of the trihydroxy side-chain starting with tartaric acid 
 
The plan started with meso-tartaric acid, which is commercially available. Reaction of 
the diethyl ester from the tartaric acid and ethanol in the presence of  pyridinium-p-
toluenosulphonate (Scheme 38) gave the diester in 40% yield. The yield was raised to 







3.2.3.2.1  Protection of the diethyl tartrate to give (117) 
 
Compound (117) was formed from the protection of the vicinal hydroxyl groups of 
(116); acetonide formation was the best choice by following the kinetic control method 
with 2,2-dimethoxypropane in dichloromethane with p-toluenesulfonic acid to give the 
protected diethyl tartate45 (117) in very low yield. Using a higher-boiling solvent raised 
the yield; boiling toluene was the solvent for the acetonide protection and that gave 
(117) in 86% yield (Scheme 38). 
 
 
      
 
Scheme 38: Synthesis of the trihydroxy side chain f rom meso-tartaric acid. Reagents and
conditions:i:TsOH, DMP ii: LiAlH4; iii: Butanoylchloride, Et3N, DCM; iv: PCL, i-pr2o.  
 
3.2.3.2.2 Reduction of the diethyl ester on diethyl R,R-2,2-dimethyl-1,3-dioxolane 
-4,5-dicarboxylate (117) 
 
To reduce the two ethyl esters on compound (117), many studies had reported that 
sodium aluminium hydride and lithium aluminium hydride have the same effect as 
reducing agents.82 Treatment of (117) with lithium aluminium hydride in 






3.2.3.2.3 Protection of the diol of S,S-4,5-Di(hydroxymethyl)-2,2,dimethyl-1,3-
dioxolane (118) with butanoate  
 
In order to avoid the difficulties that El-Hamamsy45 had with the benzyl protection of 
the diols (118), the idea of trying with an ester such as butanoate by reaction of (118) 
with butanoyl chloride in basic condition was investigated. Because the following step 
is to remove one of the stereoselective group in the meso compound, it might be 
applicable with the lipase enzyme. This protection was achieved successfully to give 
(119) in 65% yield (Scheme 38). 
 
3.2.3.2.4 Attempted hydrolysis of the formed ester S,S-4,5-di(butanoyloxymethyl)-
2,2,dimethyl-1,3-dioxolane (119) by lipase enzyme  
 
Lipase is known as a hydrolytic agent for asymmetric synthesis. It can hydrolyse the 
prochiral diesters of diols to homochiral monoacetates. There was a study that 
investigated the lipase hydrolytic action from the commercially available meso-tartaric 
acid to the diol (121) and the diacetate (122). It was determined that Pseudomonas 
cepacia lipase (PCL) hydrolyses the diacetate to monoacetate in 81%, with higher 
enantioselectivity especially in an immiscible organic solvent such as diethylether, 
diisopropyl ether or hexane, and if it is in an emulsion (organic solvent/ water) will give 
91% monoacetate. Also, it has been reported that the acetylation rate of (PCL) for a diol 
to a monoacetate is high as well giving a 91% yield at room temperature with acetic 




             
 
 
In order to hydrolyse the ester to an alcohol (122) a lipase enzyme reaction was 
attempted. Compound (119) (Scheme 39) and PCL were stirred in the phosphate buffer 
and diisopropyl ether (i-Pr2O). The reaction was monitored at pH 7 for five hours, the 
mixture was extracted with diethylether. However, there was no reaction as the starting 






















This project has focused on the development of a novel selective inhibitor of M. 
tuberculosis DHFR, based on that which was reported in a previous study.45 The target 
compounds all contain a 2,4-diaminopyrimidine moiety. The project has focused on 
exploring the DHFR binding site using a linker at position 6 containing either O or N.  
 
The synthesis of N-p-methoxybenzylamino-2,4-diamino-5-phenylpyrimidine was 
carried out by condensation of diethylphenyl malonate with guanidine, followed by 
halogenations of the carbonyl groups to create dichloro or dibromo intermediates. The 
dichloro intermediate, as well as dibromo, were successfully formed after one attempt 
with the brominating agent, phosphorus oxybromide, for the dibromo intermediate. One 
of the chlorine atoms of the dichloro intermediate was then substituted with a 4-
methoxybenzylamino group. This achieved compound was essential for both plans in 
the project. The two plans were applied after synthesizing 6-chloro-4-(4-
methoxybenzylamino)-5-phenylpyrimidine-2-amine; the other chlorine atom was 
substituted with different aminoalcohols (amino butanol, pentanol, ethanol and 
propanol) after several attempts with aromatic amines. Investigating several conditions 
such as different solvents, the presence and absence of base, and the temperature have 
achieved the best reaction conditions to replace the chlorine atom with an amino alcohol 
especially with amino butanol and pentanol but in low yields. These conditions use 
three equivalents of potassium carbonate with three equivalents of the amino alcohol at 
130°C without solvent. Then, the p-methoxybenzylamino group was successfully 
removed by DDQ oxidation. Achievement of the 2,4-diaminopyrimidine with the amino 
alcohol side chain at position 6 of the pyrimidine ring requires optimisation and several 
purifications by column chromatography. The Buchwald reaction has also been 
investigated with the dibromo intermediate to substitute one of the bromine atoms with 
aminobutanol in the presence of BINAP ligand, which has shown good results with aryl 
bromide in literature. Unfortunately, the substitution failed.  
 
The second plan was synthesizing 6-chloro-4-(4-methoxybenzylamino)-5-
phenylpyrimidine-2-amine (the essential compound for both plans), followed by the 
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synthesis of the trihydroxy side chain, to link it to position 6 of the pyrimidine ring. 
Synthesis of the trihydroxy side chain, started from the ribonolactone, followed by 
acetonide protection of the vicinal hydroxyl groups. The investigation of different 
protecting groups for the primary hydroxyl group led to a protection with the tert-
diphenyldimethylsilyl group because of its stability and bulkiness. This was followed by 
a reduction of the ester carbonyl group, and gave a good result with sodium 
borohydride, which normally does not reduce esters. The reduction of the ester resulted 
in the formation of primary and secondary hydroxyl groups. Protection of the primary 
hydroxyl group was investigated with different protecting groups, which unfortunately  
failed. Changing the synthetic strategy of the synthesis of the trihydroxy side chain 
showed good results in literature in the hydrolysis of esters, beginning with meso-
tartaric acid, followed by acetonide protection of the vicinal hydroxyl groups, followed 
by reduction to the diol with lithium borohydride, and finally esterfication of the diols 
with butonoyl chloride to test the hydrolysis of one ester by the lipase enzyme. 
Unfortunately, it was not successful. For future work after the synthesis of 6-chloro-4-
(4-methoxybenzylamino)-5-phenylpyrimidine-2-amine with different amino alcohols, 
the following is needed: 
 Optimisation of the reactions of 6-chloro-4-(4-methoxybenzylamino)-5-
phenylpyrimidine-2-amine with different amino alcohols (amino butanol, 
pentanol, ethanol and propanol), while finding a perfect way for purification. 
 Removal of the PMB group by oxidation with DDQ. 
 Testing of 4-(2-hydroxyalkyllamino)-6-(4-methoxybenzylamino)-5-
phenylpyrimidin-2-amine against the mycobacterial DHFR. 
 












Chemical reagents were purchased from Sigma, Aldrich, Fluka and Novabiochem. TLC 
was carried out on Merck aluminium-backed TLC plates Silicagel 60 F254 and viewed 
using UV light ( = 254 nm). Column chromatography was carried on silica gel 60 (35 
– 70 micron).  
All reactions were carried out under a static atmosphere of nitrogen and stirred 
magnetically at room temperature unless otherwise stated. Solutions in organic solvents 
were dried with MgSO4. 
NMR data were obtained on a Varian Mercury VX spectrometer (400 MHz). The 
chemical shifts are recorded in parts per million (ppm) relative to tetramethylsilane. 
Mass spectrometry was carried out on a microTOFTM from Bruker Daltonics (Bremen, 
Germany) using an electrospray source (ESI-TOF). Melting points were obtained using 
















                                                    
 
NaH (2.26 g, 94.2 mmol) was added carefully to dry MeOH (60 mL). Guanidine 
hydrochloride (6.00 g, 62.8 mmol ) and diethyl phenylmalonate (80) (11.6 g, 52.2 
mmol) were added to this solution of NaOMe and the mixture was stirred under reflux 
for 3 h. The solvent was evaporated. The residue, in water, was stirred with 
decolourising charcoal for 15 min. The suspension was filtered. Acetic acid ( 20 mL) 
was added to the filtrate at 80°C then the mixture was filtered to give (81) (4.80 g, 46%) 
as a white solid: mp >350C (lit.84 mp 333-336C decomp.); 1H NMR (CDCl3)  6.66 (2 
H, br, 2  OH), 7.00 (1 H, tt, J = 8, 1 Hz, Ph 4-H), 7.17 (2 H, t, J = 8 Hz, Ph 3,5-H2), 
7.53 (2 H, d, J = 8 Hz, Ph 2,6-H2), 10.43 (2 H, br, NH2); MS m/z 429.1273 (2 M + Na) 





                                                           
 
Compound (81) (4.00 g, 19.7 mmol) and phosphorus oxychloride (18.0 mL, 119 mmol) 
were stirred under reflux for 3 h. Ice was added to the solution and the mixture was 
stirred for 2 h, then the mixture was neutralised with aq. ammonia (4.0 mL, 35%). The 
precipitate was filtered off and dried to give (83) (3.9 g, 83%) as a white solid: mp 285-
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287°C (lit.65 mp 221-222C); 1H NMR (CDCl3)  5.25 (2 H, br, NH2), 7.27-7.46 (5 H, 
m, Ar). 13C NMR (CDCl3)  118 (pyrimidine 5-C), 128.26 (Ph 4-C), 128.35 (Ph 3,5-C2), 
130.27 (Ph 2,6-C2), 160.06 (pyrimidine 4,6-C2), 161.25 (pyrimidine 2-C).  
6-Chloro-4-(4-methoxybenzylamino)-5-phenylpyrimidine-2-amine (84)  
 
                                              
 
Acetic acid (3.0 mL) and 4-methoxybenzylamine (12.0 g, 87.4 mmol) were added to 
compound (83) (6.00 g, 24.9 mmol) and the mixture was heated at 130°C for 2 h. The 
cooled residue, in EtOAc, was washed with water and dried. Evaporation and 
chromatography (EtOAc / petroleum ether 1:9) gave (84) (5.8 g, 68%) as a buff oil: 1H 
NMR (CDCl3) (COSY)  3.89 (3 H, s, OMe), 4.48 (2 H, d, J = 5.8 Hz, CH2), 4.80 (1 H, 
t, J = 6 Hz, NH), 4.97 (2 H, br, NH2), 6.82 (2 H, d, J = 8.7 Hz, PMB 3,5-H2), 7.12 (2 H, 
d, J = 8.7 Hz, PMB 2,6-H2), 7.25 (2 H, m, Ph 2,6-H2), 7.36 (1 H, tt, J = 7.3, 1.6 Hz, Ph 
4-H), 7.43 (2 H, t, J = 7.0 Hz, Ph 3,5-H2); 13C NMR ((CD3)2SO) (HSQC, HMBC)  
41.70 (CH2), 55.19 (Me), 104.30 (pyrimidine 5-C), 112.10 (Ph 1-C), 113.81 (PMB 3,5-
C2), 128.75 (PMB 2,6-C2), 127.06 (Ph 4-C), 127.78 (Ph 3,5-C2), 130.92 (Ph 2,6-C2), 
131.60 (PMB 1-C), 134 (Ph 1-C), 150.20 (pyrimidine 6-C), 158.31 (PMB 4-C), 160.36 
(pyrimidine 4-C), 161.19 (pyrimidine 2-C), 1 ; MS m/z 363.0989 [M + Na]⁺ 
[C18H1735ClN4NaO requires 363.0989]. 
4-Benzylamino-6-chloro-5-phenylpyrimidine-2-amine (86) 
 




Acetic acid (3.0 mL) and benzylamine (12.0 g, 112 mmol) were added to (83) (6.00 g, 
24.9 mmol) and the mixture was heated at 130°C for 2 h. The cooled residue, in EtOAc, 
was washed with water. Drying and evaporation gave crude  (86) (7.5 g, 62%) as a 
white solid: NMR (CDCl3)  4.47 (2 H, d, J = 5.7 Hz, CH2), 4.90 (1 H, br, NH), 5.70 (2 
H, br, NH2), 7.2-7.5 (10 H, m, 2  Ph-H5).  
6-Chloro-5-phenylpyrimidine-2,4-diamine (87) 
 
                                                     
 
Compound (84) (100m g, 0.29 mmol) was stirred with DDQ (130 g, 0.58 mmol) in 
dichloromethane (0.9 mL) and methanol (0.1 mL) for 4 days, washing out with 
diethylether and  evaporation gave (87) (0.03 g, 50%) as white solid, mp ˃230°C. 
1H NMR (CD3)2SO δ 6.90 (2 H, br, NH2),  7.22 (2  H, br, NH2), 7.32 (2 H, d, J = 8.6 Ph 
2,6-H2), 7.55 (3 H, m, Ph 3,4,5-H3). 
MS m/z: 243.0390 [M + Na]⁺ [C10H935ClN4Na requires 243.0413]. 
4,6-Dibromo-5-phenylpyrimidin-2-amine (89) 
 
                                                     
 
Compound (81) (0.50 g, 2.46 mmol) and phosphorus tribromide (1.33 g, 4.91 mmol) 
were stirred together under reflux for 3 h. Ice was added to the solution and the mixture 
was stirred for 2 h, then the mixture was neutralised with aq. ammonia (4.0 mL, 35%). 
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The precipitate was filtered off and dried to give (89) (0.72 g, 86 %) as a buff solid: mp 
>230C.  
1H NMR (COSY) (CDCl3)  6.72 (2 H, br, NH2), 7.07 (1 H, t, J = 7.4 Hz, Ph 4-H), 7.24 
(2 H, t, J = 7.8 Hz, Ph 3,5-H2), 7.53 (2 H, d, J = 7.8 Hz, Ph 2,6-H2), 10.43 (2 H, br, 
NH2); 13C NMR (HMBC, HSQC)  123.00 (pyrimidine 5-C), 123.62 (1 C, Ph 4-C), 
126.04 (Ph 3,5-C2), 130.04 (Ph 2,6-C2), 151.83 (pyrimidine 4,6-C2), 159.0 (pyrimidine 




                                                 
 
Method 1 
Compound (84) (0.10 g, 0.29 mmol) was stirred with 3-aminopropanol (0.11 g, 1.5 
mmol) and K2CO3 (80 mg, 0.57 mmol) in dry DMF (1.0 mL) at 130°C for 3 d. 
Evaporation and (EtOAc / MeOH 9:1) gave (90) (0.025 g, 21%) as a pale yellow gum. 
Method 2 
Compound (84) (0.07 g, 0.20 mmol) was stirred with 3-aminopropanol (0.04 g, 0.61 
mmol) and K2CO3 (0.05 g, 0.41 mmol) at 150°C for 3 d. Chromatography (EtOAc / 
MeOH 9:1) gave (90) (0.025 g, 32%) as a pale yellow gum. 
1H NMR ((CD3)2SO) δ 1.34  (2 H, m, propyl 2-H2),  3.39  (4 H, m, propyl 1,3-H2 ), 3.75  
(3 H, s, OMe), 4.4 (2 H, d, J = 5.7 Hz NHCH2Ar), 5.37 (1 H, t, J = 6.5 Hz, OH), 5.72 (1 
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H, t, J = 7.0 Hz, NH),  6.86  (2 H, d, J = 8.0 Hz,  PMB 3,5-H2), 6.88 (2 H, d, J = 8.76 
Hz, PMB 2,6-H2), 7.19 (2 H, t, J = 8.9 Hz, Ph 2,6-H2), 7.26 (1 H, m, Ph 4-H), 7.44-7.53 
(2 H, m, Ph 3,5-H2).  
MS m/z 380.2119 [M + H]⁺ [C21H26N5O2 requires 380.2087], 402.1913 [M + Na]⁺ 
[C21H25N5NaO2 requires 402.1913]. 
4-(2-Hydroxyethylamino)-6-(4-methoxybenzylamino)-5-phenylpyrimidin-2-amine 
(91).  
                                               
Method 1 
Compound (84) (100 mg, 0.29 mmol) was stirred with K2CO3 (500 mg, 3.6 mmol) and 
2-aminoethanol (170 mg, 2.8 mmol) in dry DMF (1.0 mL) at 130°C for 3 d under N2. 
Evaporation and  chromatography (EtOAc / MeOH 9:1) gave (91) (30 mg, 30%) as a 
pale buff gum. 
Method 2 
Compound (84) (70 mg, 2.05 mmol) was heated with K2CO3 (700 mg, 6.15 mmol) and 
2-aminoethanol (370 mg, 6.15 mmol) at 150°C for 3 d under N2. Evaporation and 
chromatography (EtOAc / MeOH 9:1) gave (91) (30 mg, 40%) as a buff gum:  
1H NMR (CD3OD) (COSY)  3.60 (2 H, t, J = 5.8 Hz, CH2CH2ND), 3.87 (2 H, t, J = 
6.0 Hz, CH2OD), 3.80 (3 H, s, Me), 4.82  (2 H, d, J = 6.2 Hz, NHCH2Ar), 6.90 (2 H, d, 
J = 8.7 Hz, PMB 3,5-H2), 7.20 (2 H, d, J = 8.8 Hz, PMB 2,6-H2), 7.33 (2 H, d, J = 6.9 
Hz, Ph 2,6-H2), 7.41 (1 H, t, J = 7.4 Hz, Ph 4-H), 7.50 (2 H, t, J = 7.3 Hz, Ph 3,5-H2); 
13C NMR (HSQC, HMBC)  43.62  (CH2NH), 43.77 (NCH2Ar), 55.84 (Me), 60.47 
(CH2OH), 114.32 (PMB 3,5-C2), 128.02 (pyrimidine 4-C), 129.41 (PMB 2,6-C2), 
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129.78 (Ph 2,6-C2), 130.54 ( Ph 3,5-C2), 132.39 (Ph 4-C), 134.61 (PMB 1-C), 160.49 
(PMB 4-C), 160.81 (pyrimidine 5-C), 162.33 (pyrimidine 2-C), 165.80 (pyrimidine 6-
C). 
 MS m/z 388.1755 [M + Na]⁺ [C20H23N5O2 requires 388.1749]. 
4-(4-Hydroxybutylamino)-6-(4-methoxybenzylamino)-5-phenylpyrimidin-2-amine 
(92).  









Compound (84) (100 mg, 0.29 mmol) was stirred with K2CO3 (0.08 g, 0.57 mmol) and 
4-aminobutanol (0.13 g, 1.46 mmol) in dry DMF (1.0 mL) at 130°C for 3 d. 
Evaporation and chromatography (EtOAc / MeOH 9:1) gave (92) (0.030 g, 26%) as 
colourless oil.  
 
Method 2 
Compound (84) (100 mg, 0.29 mmol) was heated with K2CO3 (0.08 g, 0.57 mmol) and  
4-aminobutanol (0.13 g, 1.46 mmol) at 150°C for 3 d. Evaporation and  chromatography 
(EtOAc / MeOH 9:1) gave (92) (20 mg, 15%) as a colourless gum. 
1H NMR ((CD3)2SO)  1.45 (4 H, m, butyl 2,3-H4),  3.11  (2 H, q, J = .0 Hz, butyl 1-
H4), 3.45  (2 H, t, J = 5.8 Hz, butyl 4-H2), 3.75 (3 H, s, Me), 4.39  (2 H, d, J = 5.6  Hz, 
ArCH2NH), 4.61 (1 H, t, J = 6.0 Hz, OH), 5.09  (1 H, t, J = 5.5 Hz, NH), 5.60 (2 H, br, 
NH2),  6.87  (2 H, d, J =8.3 Hz,  PMB 3,5-H2), 7.20 (2 H, d, J = 8.6 Hz, PMB 2,6-H2), 
7.24 (2 H, d, J = 6.8 Hz, Ph 2,6-H2), 7.39  (1 H, t, J = 7.5 Hz, Ph 4-H), 7.50 (2 H, t, J = 
7.4 Hz, Ph 3,5-H2). 
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 MS m/z 416.2091 [M + Na]⁺, [C22H27N5NaO2 requires 416.2062]. 
4-(5-Hydroxypentylamino)-6-(4-methoxybenzylamino)-5-phenylpyrimidin-2-amine 
(93).  
                                              
Method 1 
Compound (84) (100 mg, 0.29 mmol) was heated with K2CO3 (50 mg, 0.41 mmol)  and 
5-aminopentanol (150 mg, 1.45 mmol) dry DMF (1.0 mL)  at 130°C for 3 d. 
Evaporation and  chromatography (EtOAc / MeOH 9:1) gave (93) (20 mg, 19%) as a 
colourless gum.  
Method 2 
Compound (84) (70 mg, 0.20 mmol) was heated with K2CO3 (50 mg, 0.36  mmol) and 
5-aminopentanol  (60 mg, 0.58 mmol) at 150°C for 3 d under N2. Evaporation and  
chromatography (EtOAc / MeOH 9:1) gave (93) (23 mg, 28%)  as a colourless gum:  1H 
NMR ((CD3)2SO) (COSY)   1.19 (3 H, q, J = 6.5 Hz, pentyl 3-H2), 1.36 (3 H, q, J = 
6.0 Hz, pentyl 4-H4), 3.17  (2 H, qr, J = 7.0 Hz, pentyl 1-H2), 3.34 (2 H, t, J = 7.0 Hz, 
pentyl 5-H2), 3.69  (3 H, s, Me), 4.35 (2 H, d, J = 6.5 Hz, ArCH2NH),  4.54 (1 H, t, J = 
6.0 Hz, OH), 5.04 (1 H, t, J = 6.0 Hz, NH), 5.60 (2 H, br, NH2), 6.81 (2 H, d, J = 6.5 
Hz, PMB 3,5-H2), 7.14 (2 H, d, J = 9.0 Hz, PMB 2,6-H2), 7.19  (2 H, d, J = 8.0 Hz, Ph 
2,6-H2), 7.33 (1 H, t, J = 7.4 Hz, Ph 4-H), 7.46  (2 H, t, J = 7.5 Hz, Ph 3,5-H2); 13C 
NMR (HSQC, HMBC)  11.87 (pentyl 3-C), 29.49 (pentyl 2-C), 32.26 (pentyl 4-C), 
41.0 (pentyl 1-C), 60.64 (pentyl 5-C), 54.95 (Me), 42.78 (CH2PMB), 113.44 (PMB 3,5-
C2), 127.06 (pyrimidine 4-C), 128.26 (PMB 2,6-C2), 129.61 (Ph 2,6-C2), 131.48 (Ph3,5-
C2), 133.26 (Ph 4-C), 134.00 (PMB 1-C), 157.83 (PMB 4-C), 159.49 (pyrimidine 5-C), 
159.93 (pyrimidine 2-C), 161.53 (pyrimidine 6-C);  
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Compound (84) (0.10 g, 0.29 mmol) was heated with K2CO3 (80 mg, 0.57 mmol)  and 
4-aminobutanol  (130 mg, 1.5 mmol)  in 2-methoxyethanol (1.0 mL) at 130°C for 3 d. 
Evaporation and chromatography (EtOAc / MeOH 9:1)  gave (94) (0.05 mg, 45 %) as a 
white solid: mp 85-87C; 1H NMR ((CD3)2SO)  3.22 (3 H, s, CH2OMe), 3.52 (2 H, t, J 
= 5.1 Hz, CH2OMe), 3.75  (3 H, s, ArOMe), 4.30 (2 H, t, J = 4.9 Hz, CH2O-
pyrimidine), 4.45 (2 H, d, J = 6.2 Hz, NHCH2Ar), 5.83 (1 H, t, J = 5.9 Hz, NH), 6.1 (2 
H, br, NH2),  6.88  (2 H, d, J = 8.5 Hz,  PMB 3,5-H2), 7.20-7.30 (5 H, m, PMB 2,6-H2, 
Ph 2,4,6-H3), 7.42 (2 H, t, J = 7.5 Hz, Ph 3,5-H2).  
MS m/z 403.1765 [M + Na]⁺ [C21H24N4NaO3 requires 403.1746]. 
4-((2,6-Diamino-5-phenylpyrimidin-4-yl)amino)butan-1-ol (95)  
 











Compound (87)  (0.34 g, 0.67 mmol) was stirred with K2CO3 (60 mg, 0.45 mmol) and 
4-aminobutanol (5 mg, 0.22 mmol) in dry DMF (1.0 mL)  at 130°C for 3 d. The mass 
spectrum showed the compound (95) but it could not be isolated from the mixture. 
Method 2 
DDQ (20 mg, 0.1 mmol) was stirred with (92) (20 mg, 0.05 mmol) in dichloromethane 
(0.9 mL) and methanol (0.1 mL) for 4 d. The compound (95) could not be isolated from 
the mixture but it was identifiable by NMR and mass spectroscopy. 
1H NMR ((CD3)2SO) δ 1.45 (4 H, m, butyl 2,3-H4),  3.0-3.9  (4 H, m, butyl 1,4-H4), 5.8 
(2 H, br, NH2),  7.20 (2 H, d, J = 7.28 Hz, Ph 2,6-H2), 7.60  (3 H, m, Ph 3,4,5-H3). 
MS m/z 247.1659 [M + H]⁺ [C14H20N5O requires 274.1668]. 
5-((2-Amino-6-5-phenylpyrimidin-4-yl)amino)pentan-1-ol (96) 
 
                                        
 
DDQ (20 mg, 80  mol) was stirred with (93) (20 mg, 40 mol) in CH2Cl2 (0.9 mL) and 
MeOH (0.1 mL) for 4 d. Compound (96) could not be isolated from the mixture but it 
was identified by NMR and mass spectroscopy. 
1H NMR ((CD3)2SO) δ 1.28 -1.45  (6 H, m, pentyl 2,3,4-H6),  3.10-3.9  (4 H, m, pentyl 
1,5-H4), 7.26 (2 H, d, J = 8.6 Hz, Ph 2,6-H2), 7.50 (1 H, t, J = 7.3  Hz, Ph 4-H), 7.60 (2 
H, t, J = 7.8 Hz, Ph 3,5-H2). 






                                                    
 
Compound (94) (0.100 g, 0.26 mmol) was stirred with  DDQ (0.11 g, 0.52 mmol) in 
dichloromethane (0.9 mL) and methanol (0.1 mL) for 4 d. Evaporation of the solvent 
and washing the residue with diethyl ether  gave (97) (0.045 g, 70%) as a pale yellow 
gum. 
1H NMR ((CD3)2SO) δ 3.22 (3 H, s, Me), 3.55 (2 H, t, J = 4.6 Hz, CH2OMe),  4.40  (2 
H, t, J = 4.9 Hz, CH2O-pyrimidine), 5.80 (2 H, br, NH2), 7.20 (2 H, d, J = 7.0 Ph 2,6-
H2), 7.38( 1 H, t, J = 7.2 Hz, Ph 4-H), 7.50 (2 H, t, J = 7.2 Hz, Ph 2,6-H2). 
MS m/z 283.1171 [M + Na]⁺ [C13H16N4NaO2 requires 283.1170]. 
4-((2-Amino-6-chloro-5-phenylpyrimidin-4-yl)amino)butan-1-ol (98) 
 
                                         
 
K2CO3 (0.56 g, 4.1 mmol) was stirred with (83) (1.0 g, 4.2 mmol) and 4-aminobutanol 
(0.37 g, 4.2 mmol) in EtOH (5.0 mL) at 60°C for 16 h. Evaporation and 
chromatography (EtOAc/ MeOH 9:1) gave (98) (0.67 g, 55%) as a white solid. 
1H NMR ((CD3)2SO) (COSY) δ 1.39  (2 H, qn ,J = 7.4 Hz, butyl 3-H2), 1.49 (2 H, qn, J 
= 7.0 Hz, butyl 2-H2),  3.28  (2 H, q, J = 6.3 Hz, butyl 1-H2), 3.40 (2 H, q, J = 5.3 Hz, 
butyl 4-H2),  4.36  (1 H, t, J =5.1 Hz, OH), 5.60  (1 H, br, NH), 6.45 (2 H, s, NH2),  7.25  
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(2 H, d, J = 6.8 Hz, Ph 2,6-H2),  7.44  (1 H, t, J = 7.3 Hz , Ph 4-H), 7.50 (2  H, t, J = 7.0 
Hz, Ph 3,5-H2). 
13C NMR (HMBC) (HSQC) δ 25.61 (1 C, CH2CH2NH), 29.82 (1 C, CH2CH2OH), 41.0 
(1 C, CH2OH), 60.0 (1 C, CH2NH), 105 (1 C, CNH2), 127.71 (1 C, Ph 4-C), 128.90 (2 
C, Ph 3.5-C2), 130.82 (2 C, Ph 2 ,6-C2), 133,0 (1 C, Ph 1-C), 151 (1 C, C-Cl). M.p 145-
147°C. 
MS m/z: 293.1178 [M + H]⁺ [C14H1835ClN4O requires 293.1169]. 
3aR,6R,6aR-2,2-Dimethyl-6-hydroxymethyldihydrofuro[3,4-d][1,3]dioxol-4(3H)-
one76 (112) 
                                                      
                                                  
A mixture of D-ribonolactone  (4.35 g, 29.3 mmol), 2,2-dimethoxypropane (15.2 g, 146 
mmol) and pyridinium 4-methylbenzenesulfonate (195 mg, 0.79 mmol) was heated at 
60°C for 4 h; excess reagent was then evaporated. The residue, in EtOAc, was washed 
with sat. aq. NaHCO3 and dried. The evaporation residue was dissolved in THF (15.0 
mL) and aq. HCl (0.1 M, 10.0 mL) and the mixture was stirred for 10 min at room 
temperature. The solvent was evaporated and the residue was dissolved in EtOAc. This 
solution was washed with sat. aq. NaHCO3, then dried. Evaporation gave (111) (3.00 g, 
62%) as a white solid: mp 135-137C (lit.76 mp 135-137C); 1H NMR (CDCl3) (COSY , 
NOESY)  1.42 (3 H, s, Meendo), 1.52 (3 H, s, Meexo), 3.84 (1 H, dd, J = 12.1, 1.8 Hz, 
HOCH), 4.02 (1 H, dd, J = 12.1, 2.1 Hz, HOCH), 4.65 (1 H, t, J = 2.1 Hz, 6-H), 4.81 (1 
H, d, J = 5.6 Hz, 6a-H), 4.86 (1 H, d, J = 5.6 Hz, 3a-H); 13C NMR (CDCl3) (HSQC , 
HMBC) 25.48 (Meendo), 26.71 (Meexo), 62.11 (CH2OH), 75.59 (3a-C), 78.20 (6a-C), 









                                             
Compound (112) (5.00 g, 21.1 mmol) and NaH (60% in oil, 1.27 g, 32 mmol) were 
mixed together in dry DMF (18.3 mL), then 4-methoxybenzyl chloride (5.00 g, 32 
mmol) was added and the mixture was stirred overnight. The evaporation residue, in 
diethyl ether, was washed with water. Drying, evaporation and chromatography 
(petroleum ether/ EtOAc) (3:1) gave (113) (1.63 g, 24%) as pale yellow oil (lit.78 oil): 
1H NMR (CDCl3)  1.28 (3 H, s, Me), 1.38 (3 H, s, Me), 3.55 (1 H, dd, J = 10.4, 2.4 Hz, 
PMBOCH), 3.59 (1 H, dd, J = 10.4, 2.4 Hz, PMBOCH), 3.72 (3 H, s, Me), 4.32 (1 H, d, 
J = 12.4 Hz, ArCH), 4.40 (1 H, d, J = 12.4 Hz, ArCH), 4.53 (1 H, t,  J = 2.3 Hz, 6-H), 
4.60 (1 H, d, J = 6.4 Hz, 6a-H), 4.66 (1 H, d, J = 6.4 Hz, 3a-H), 6.80 (2 H, d, J = 9.2 Hz, 
Ar 3,5-H2), 7.10 (2 H, d, J = 8.8 Hz, Ar 2,6-H2); 13C NMR (CDCl3) δ 25.55 (Me), 26.72 
(Me), 55.22 (OMe), 68.65, 73.50, 75.65, 78.34, 81.07, 113.05 (Ar 1-C), 113.93 (Ar 3,5-




                                             
 
Compound (112) (3.00 g, 15.9 mmol), imidazole (2.00 g, 29.3 mmol) and anhydrous 
DMF (20 mL) were mixed; tert-butyldiphenylsilyl chloride (4.20 g, 14.5 mmol) was 
added and the mixture was stirred at room temperature overnight. The reaction mixture 
was poured into water and extracted with diethyl ether. Drying and evaporation gave 
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(114) (4.20 g, 62%) as a white solid: mp 77-80°C (lit.85 mp 92-94C); 1H NMR (CDCl3) 
(COSY , NOESY)  1.04 (9 H, s, But), 1.40 (3 H, s, Meendo), 1.49 (3 H, s, Meexo), 3.75 
(1 H, dd,  J = 11.5, 1.5 Hz, SiOCH), 3.91 (1 H, dd, J = 11.5, 2.5 Hz, SiOCH), 4.58 (1 H, 
t, J = 1.8 Hz, 6-H), 4.73 (1 H, d, J = 5.6 Hz, 6a-H), 4.90 (1 H, d, J = 5.6 Hz, 3a-H), 
7.35-7.49 (6 H, m, Ph), 7.60-7.64 (3 H, Ph), 7.72 (1 H, dd, J = 8.0, 2.0 Hz, Ph); 13C 
NMR (CDCl3) (HSQC, HMBC)  25.5 (Meendo), 26.50 (Meexo), 26.69 (Me3), 29.69 (C-
Si), 63.54 (CH2O), 75.8 (3a-C), 78.4 (6a-H), 82.32 (6-C), 127.70 (2-C), 128.00 (2C-Ar), 
129.64 (C-Ar), 130.17 (C-Ar), 131.52 (C-Ar), 132.35 (C-Ar), 134.78 (C-Ar), 135.43 
(2C-Ar), 135.60 (2C-Ar), 174.09 (4-C). 
 (R)-2-(tert-butyldiphenylsilyloxy)-1-((4R,5S)-5-(hydroxymethyl)-2,2-dimethyl-1,3-
dioxolan-4-yl)ethanol (115)  
 
                                         
Compound (114) (3.00 g, 7.03 mmol) in dry EtOH (25 mL) at 0°C was stirred and 
NaBH4 (400 mg, 10.6 mmol) was added. The mixture was stirred for 2 h. NH4Cl (500 
mg, 9.3 mmol) was added and the mixture was stirred for 5 min, then filtered and 
evaporated to give an oil, which was purified by chromatography (EtOAc / petroleum 
ether 1:9) to give (115) (2.7 g, 89%) as a colourless oil: 1H NMR (CDCl3)  1.18 (9 H, 
s, But), 1.28 (3 H, s, Me), 1.30 (3 H, s, Me), 3.06 (1 H, br, 2  OH), 3.75 (1 H, dd, J = 
10.5, 6.5, SiOCH), 3.75-3.90 (3 H, m, CH2OH + CHOH), 3.90 (1 H, dd, J = 10.5, 3.0 
Hz, SiOCH), 4.11 (1 H, dd, J = 9.5, 6.0 Hz, 4-H), 4.35 (1 H, dt, J = 7.5, 5.5 Hz, 5-H), 
7.39-7.67 (10 H, 2  Ph); 13C NMR (CDCl3) (HSQC , HMBC)  19.29 (C-Si), 25.22 
(Me), 26.87 (Me3), 27.74 (Me), 60.86 (CH2OH), 65.34 (CH2OSi), 69.68 (CHOH), 76.53 
(5-C), 77.56 (4-C), 108.53 (2-C), 127.82 (Ph 3,5-C2), 127.86 (Ph’ 3,5-C2), 129.29 (Ph 4-





Diethyl -2,3-dihydroxybutanedioate45 (116) 
 
                                                          
 
meso-Tartaric acid (1.00 g, 6.7 mmol) was boiled under reflux with 4-methyl-
benzenesulfonic acid (2.30 g, 13.3 mmol) in EtOH (8.0 mL) for 16 h. The solvent was 
evaporated. The residue, in ethyl acetate, was washed with water and dried. The solvent 
was evaporated  to give (116) (0.80 g, 58%) as white crystals: 1H NMR (CDCl3) 
(COSY)  1.30 (6 H, m, 2   Me), 3.82 (2 H, s,  2  OH), 4.15-4.30 (4 H, m, 2  CH2), 
4.80 (2 H, s, 2  CHOH); 13C NMR (HSQC, HMBC)  14.03 (2  Me), 62.29 (2  
CH2), 72.81 (2  CHOH), 171.01 (2  C=O). 
Diethyl R,R-2,2-dimethyl-1,3-dioxolane-4,5-dicarboxylate45(117) 
 
                                                                                                   
Compound (116)  (1.00 g, 4.66 mmol) was stirred with 2,2-dimethoxypropane (0.53 g, 
5.3 mmol) and 4-methylbenzenesulfonic acid (4.4 mg, 0.02 mmol) in toluene (50 mL) at 
80°C with 4 Ǻ molecular sieves (0.5 g) for 16 h. Na2CO3 (5.0 mg, 0.06 mmol) was 
added. The mixture was filtered and dried and  the solvent was evaporated to give (117) 
(0.98 g, 86%) as colourless oil (lit.86 oil): 1H NMR (CDCl3)  1.25 (6 H, t, J = 7.2 Hz, 2 
 CH2CH3), 1.38 (3 H, s, C-Me), 1.62 (3 H, s, C-Me), 4.17 (4 H, m, 2  CH2CH3), 4.78 







                                                   
LiAlH4 (0.33 g, 8.25 mmol) in dry THF (3.3 mL) was heated for 30 min; (117) (1.0 g, 
8.3 mmol) was added and the mixture was heated under reflux for 5 h. After cooling, 
water (3.0 mL), aq. NaOH (4 M, 3.0 mL) and water (9 mL) were added. Filtration and 
evaporation gave (118) (0.74 g, 55%) as a pale yellow oil (lit.87 oil): 1H NMR (CDCl3)  
1.38 (3 H, s, Me), 1.62 (3 H, s, Me), 3.70 (2 H, dd, J = 11.5, 6.1 Hz, 2  CHHOH), 3.80 
(2 H, dd, J = 11.5, 5.2 Hz, 2  CHHOH), 3.90 (2 H, br, 2   OH),  4.30 (2 H, t, J = 4 Hz, 
4,5-H2); 13C NMR (HSQC, HMBC)  25.60 (C-Meendo), 27.49 (C-Meexo), 61.59 (4,5-
C2), 78.90 (2  CH2OH), 109.55 (2-C). 
S,S-4,5-Di(butanoyloxymethyl)-2,2,dimethyl-1,3-dioxolane (119) 
                                           
To (118) (1.0 g, 5.0 mmol) in dichloromethane (5.0 mL), butanoyl chloride (1.17 g, 11 
mmol) in dichloromethane (2.0 ml) was added, followed by triethylamine (2.50 g, 24 
mmol). The mixture was stirred for 16 h. The solvent was evaporated. The residue, in 
dichloromethane, was washed with water and dried. Evaporation and chromatography 
(EtOAc / petroleum ether) (1:3) gave (119) (1.4 g, 65%) as a colourless oil: 1H NMR 
(CDCl3)  0.96 (6  H, t, J = 7.4 Hz, 2  butanoyl 4-H3), 1.36 (3 H, s, C-Me), 1.47  (3 H, 
s, C-Me), 1.65  (4 H, sextet, J = 7.4 Hz, 2  butanoyl 3-H2), 2.43  (4 H, t, J = 7.5 Hz, 2  
butanoyl 2-H2), 4.1 (2 H, dd, J = 11.6, 6.4 Hz, 2  CHHO2CPr), 4.28 (1 H, dd, J = 11.0, 
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